Author: "Johnson NP" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Johnson NP"' showing total 452 results

Start Over Author "Johnson NP"

452 results on '"Johnson NP"'

1. Dynamic tests of ovarian reserve: a systematic review of diagnostic accuracy

Author: Maheshwari, Abha, Gibreel, Ahmed, Bhattacharya, Siladitya, and Johnson, NP
Published: 2009
Full Text: View/download PDF

2. Top 10 priorities for future infertility research: an international consensus development study

Author: Duffy, JMN, Adamson, GD, Benson, E, Bhattacharya, S, Bofill, M, Brian, K, Collura, B, Curtis, C, Evers, JLH, Farquharson, RG, Fincham, A, Franik, S, Giudice, LC, Glanville, E, Hickey, M, Horne, AW, Hull, ML, Johnson, NP, Jordan, V, Khalaf, Y, Knijnenburg, JML, Legro, RS, Lensen, S, MacKenzie, J, Mavrelos, D, Mol, BW, Morbeck, DE, Nagels, H, Ng, EHY, Niederberger, C, Otter, AS, Puscasiu, L, Rautakallio-Hokkanen, S, Sadler, L, Sarris, I, Showell, M, Stewart, J, Strandell, A, Strawbridge, C, Vail, A, van Wely, M, Vercoe, M, Vuong, NL, Wang, AY, Wang, R, Wilkinson, J, Wong, K, Wong, TY, Farquharf, CM, Duffy, JMN, Adamson, GD, Benson, E, Bhattacharya, S, Bofill, M, Brian, K, Collura, B, Curtis, C, Evers, JLH, Farquharson, RG, Fincham, A, Franik, S, Giudice, LC, Glanville, E, Hickey, M, Horne, AW, Hull, ML, Johnson, NP, Jordan, V, Khalaf, Y, Knijnenburg, JML, Legro, RS, Lensen, S, MacKenzie, J, Mavrelos, D, Mol, BW, Morbeck, DE, Nagels, H, Ng, EHY, Niederberger, C, Otter, AS, Puscasiu, L, Rautakallio-Hokkanen, S, Sadler, L, Sarris, I, Showell, M, Stewart, J, Strandell, A, Strawbridge, C, Vail, A, van Wely, M, Vercoe, M, Vuong, NL, Wang, AY, Wang, R, Wilkinson, J, Wong, K, Wong, TY, and Farquharf, CM
Abstract: STUDY QUESTION: Can the priorities for future research in infertility be identified? SUMMARY ANSWER: The top 10 research priorities for the four areas of male infertility, female and unexplained infertility, medically assisted reproduction, and ethics, access, and organization of care for people with fertility problems were identified. WHAT IS KNOWN ALREADY: Many fundamental questions regarding the prevention, management, and consequences of infertility remain unanswered. This is a barrier to improving the care received by those people with fertility problems. STUDY DESIGN, SIZE, DURATION: Potential research questions were collated from an initial international survey, a systematic review of clinical practice guidelines, and Cochrane systematic reviews. A rationalized list of confirmed research uncertainties was prioritized in an interim international survey. Prioritized research uncertainties were discussed during a consensus development meeting. Using a formal consensus development method, the modified nominal group technique, diverse stakeholders identified the top 10 research priorities for each of the categories male infertility, female and unexplained infertility, medically assisted reproduction, and ethics, access, and organization of care. PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, people with fertility problems, and others (healthcare funders, healthcare providers, healthcare regulators, research funding bodies and researchers) were brought together in an open and transparent process using formal consensus methods advocated by the James Lind Alliance. MAIN RESULTS AND THE ROLE OF CHANCE: The initial survey was completed by 388 participants from 40 countries, and 423 potential research questions were submitted. Fourteen clinical practice guidelines and 162 Cochrane systematic reviews identified a further 236 potential research questions. A rationalized list of 231 confirmed research uncertainties were entered into an interim prioriti
Published: 2021

3. A core outcome set for future endometriosis research: an international consensus development study

Author: Duffy, Jmn, Hirsch, M, Vercoe, M, Abbott, J, Barker, C, Collura, B, Drake, R, Evers, Jlh, Hickey, M, Horne, Aw, Hull, Ml, Kolekar, S, Lensen, S, Johnson, Np, Mahajan, V, Mol, Bw, Otter, A‐s, Puscasiu, L, Rodriguez, Mb, Rombauts, L, Vail, A, Wang, R, Farquhar, Cm, Daniels, Jane P, Lim, Arianne C, Edmonds, Katie, Maclean, Claire E, Appleton, Amy C, Skelton, Sarah, Byrne, Dominic L, White, Rebecca K, Sardo, Margarida, Fowles, Rebecca C, Ata, Baris, Richatd, Sarah A, Puig Ybanez, Casandra C, Peterson, Matthew C, Elms, Jasmin L, Parks, Ann, De Bie Rocks, Bianca L F, Roe, Jodie C, Doran, Ruby, Ceccaroni, Marcello, Ferreira, Ceu A, Dias, Sofia, Pinnington, Tracey, Laupa‐santiago, Paula, Turner, Marie C, Schreurs, Anneke M F, Baggot, Eleanor, Socolov, Razvan V, Yossry, Menem, Hodges, Tania M, Barbossa, Marina W P, Mures, Târgu, Lytwyn, Tracy L, Egan‐reid, Sophia E L, Devlin, Susanna C L, Crees, Kira S, Baldwin, Bethany C, Scott, James R, Gravolin, Amy K, Chapman, Errin F, Bartley, Stephanie N, Hamilton, Alicia J, Thorpe, Kirstie J, Carmody, Denise M, Eyeson, Joanna, Davis, Madeleine D, Henry, Jo, Armour, Mike, Cummings, Presley Y F V, Cook, Lisa A, and RS: GROW - R4 - Reproductive and Perinatal Medicine
Subjects: Research design, endometriosis, medicine.medical_specialty, Biomedical Research, Consensus, Delphi Technique, Endpoint Determination, Health Personnel, Population, Endometriosis, modified nominal group technique, core outcome set, Miscarriage, 03 medical and health sciences, 0302 clinical medicine, Consensus development study, medicine, Humans, Prospective Studies, Intensive care medicine, education, Pregnancy, education.field_of_study, 030219 obstetrics & reproductive medicine, Ectopic pregnancy, business.industry, Obstetrics and Gynecology, medicine.disease, Research Personnel, Systematic review, Research Design, Female, Live birth, business, modified delphi method
Abstract: Objective To develop a core outcome set for endometriosis. Design Consensus development study. Setting International. Population One hundred and sixteen healthcare professionals, 31 researchers and 206 patient representatives. Methods Modified Delphi method and modified nominal group technique. Results The final core outcome set includes three core outcomes for trials evaluating potential treatments for pain and other symptoms associated with endometriosis: overall pain; improvement in the most troublesome symptom; and quality of life. In addition, eight core outcomes for trials evaluating potential treatments for infertility associated with endometriosis were identified: viable intrauterine pregnancy confirmed by ultrasound; pregnancy loss, including ectopic pregnancy, miscarriage, stillbirth and termination of pregnancy; live birth; time to pregnancy leading to live birth; gestational age at delivery; birthweight; neonatal mortality; and major congenital abnormalities. Two core outcomes applicable to all trials were also identified: adverse events and patient satisfaction with treatment. Conclusions Using robust consensus science methods, healthcare professionals, researchers and women with endometriosis have developed a core outcome set to standardise outcome selection, collection and reporting across future randomised controlled trials and systematic reviews evaluating potential treatments for endometriosis. TWEETABLE ABSTRACT: @coreoutcomes for future #endometriosis research have been developed @jamesmnduffy.
Published: 2020

4. Top 10 priorities for future infertility research: an international consensus development study

Author: Duffy, JMN, Adamson, GD, Benson, E, Bhattacharya, S, Bofill, M, Brian, K, Collura, B, Curtis, C, Evers, JLH, Farquharson, RG, Fincham, A, Franik, S, Giudice, LC, Glanville, E, Hickey, M, Horne, AW, Hull, ML, Johnson, NP, Jordan, V, Khalaf, Y, Knijnenburg, JML, Legro, RS, Lensen, S, MacKenzie, J, Mavrelos, D, Mol, BW, Morbeck, DE, Nagels, H, Ng, EHY, Niederberger, C, Otter, AS, Puscasiu, L, Rautakallio-Hokkanen, S, Sadler, L, Sarris, I, Showell, M, Stewart, J, Strandell, A, Strawbridge, C, Vail, A, van Wely, M, Vercoe, M, Vuong, NL, Wang, AY, Wang, R, Wilkinson, J, Wong, K, Wong, TY, Farquhar, CM, Duffy, JMN, Adamson, GD, Benson, E, Bhattacharya, S, Bofill, M, Brian, K, Collura, B, Curtis, C, Evers, JLH, Farquharson, RG, Fincham, A, Franik, S, Giudice, LC, Glanville, E, Hickey, M, Horne, AW, Hull, ML, Johnson, NP, Jordan, V, Khalaf, Y, Knijnenburg, JML, Legro, RS, Lensen, S, MacKenzie, J, Mavrelos, D, Mol, BW, Morbeck, DE, Nagels, H, Ng, EHY, Niederberger, C, Otter, AS, Puscasiu, L, Rautakallio-Hokkanen, S, Sadler, L, Sarris, I, Showell, M, Stewart, J, Strandell, A, Strawbridge, C, Vail, A, van Wely, M, Vercoe, M, Vuong, NL, Wang, AY, Wang, R, Wilkinson, J, Wong, K, Wong, TY, and Farquhar, CM
Abstract: STUDY QUESTION: Can the priorities for future research in infertility be identified? SUMMARY ANSWER: The top 10 research priorities for the four areas of male infertility, female and unexplained infertility, medically assisted reproduction and ethics, access and organization of care for people with fertility problems were identified. WHAT IS KNOWN ALREADY: Many fundamental questions regarding the prevention, management and consequences of infertility remain unanswered. This is a barrier to improving the care received by those people with fertility problems. STUDY DESIGN, SIZE, DURATION: Potential research questions were collated from an initial international survey, a systematic review of clinical practice guidelines and Cochrane systematic reviews. A rationalized list of confirmed research uncertainties was prioritized in an interim international survey. Prioritized research uncertainties were discussed during a consensus development meeting. Using a formal consensus development method, the modified nominal group technique, diverse stakeholders identified the top 10 research priorities for each of the categories male infertility, female and unexplained infertility, medically assisted reproduction and ethics, access and organization of care. PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, people with fertility problems and others (healthcare funders, healthcare providers, healthcare regulators, research funding bodies and researchers) were brought together in an open and transparent process using formal consensus methods advocated by the James Lind Alliance. MAIN RESULTS AND THE ROLE OF CHANCE: The initial survey was completed by 388 participants from 40 countries, and 423 potential research questions were submitted. Fourteen clinical practice guidelines and 162 Cochrane systematic reviews identified a further 236 potential research questions. A rationalized list of 231 confirmed research uncertainties was entered into an interim prioritization s
Published: 2020

5. 10th Annual scientific session September 29–October 2, 2005 Seattle, Washington

Author: Hacker, M, Jakobs, T, Matthiesen, F, Vollmar, C, Nikolaou, K, Becker, C, Knez, A, Pfluger, T, Tiling, R, Hahn, K, Iwanochko, RM, Petrovici, R, Lee, DS, Husain, M, Woo, A, Siu, S, Masry, HZ El, Jaradat, Z, Khan, BR, Kalaria, VG, Mahenthiran, J, Raiesdana, A, Sawada, SG, Shah, DP, Virnich, DE, Ward, RP, Gundeck, EL, Williams, KA, Spencer, KT, Lang, RM, Akutsu, Y, Gewirtz, H, Gregory, SA, Zervos, GD, Thomas, GS, Yasuda, T, Duvall, WL, Croft, LB, Pungoti, C, Henzlova, MJ, Hage, FG, Heo, J, Iskandrian, AE, Johnson, NP, Leonard, SM, Kansal, P, Wu, E, Holly, TA, Michelena, HI, Stepnowski, D, Frain, V, Dempsey, DT, Kowalski, C, Van Decker, WA, Smanio, P, Rodrigues, F, Meneghelo, R, Mastrocolla, L, Thorn, A, Piegas, L, Beraldo, P, Mello, R, Tebexreni, S, ten Cate, TJF, Visser, FC, Panhuyzen-Goedkoop, NM, Verzijlbergen, JF, van Hemel, NM, Thompsen, J, Athar, H, Sainani, V, O’Sullivan, D, Leka, I, Heller, GV, Jansen, M, Grasman, M, Stier, A, Konnann, O, Silva, JA, Vitola, JV, Cunha, C, Cerci, MS, Ribeiro, OF, Jansen, MHA, Grasman, ME, Zukovski, T, Mickevicz, C, Visser, F, Snyder, K, Polepalle, D, Nichols, KJ, Dim, U, Akinboboye, OO, Vijay Anand, D, Lim, E, Nagar, K, Raval, U, Lahiri, A, Elhendy, A, Huurman, A, Schinkel, AF, Bax, JJ, van Domburg, RT, Valkema, R, Poldermans, D, Heiba, SI, Katzel, JA, Altinyay, E, Milarodovic, R, Castellon, I, Raphael, B, Abdel-Dayem, HA, Coppola, J, Heston, TF, Høilund-Carlsen, PF, Johansen, A, Vach, W, Christensen, HW, Møldrup, M, Haghfelt, T, Kumar, A, Stricker, S, Das, MK, Oddis, CV, Byrne, D, Myers, JS, Churchwell, AL, Churchwell, KB, Nichols, KJ, Dim, U, Wang, Y, Akinboboye, OO, Bergmann, SR, Druz, RS, Gopal, AS, Borges, A, Ngai, K, Chen, J, Caputlu-Wilson, SF, Shi, H, Galt, JR, Faber, TL, Garcia, EV, Cole, V, Habtemarkos, R, Sun, L, Lacy, J, Kjaer, A, Cortsen, A, Federspiel, M, Holm, S, O’Connor, M, Hesse, B, Lewin, HC, Hyun, MC, Carboni, GP, Tavolozza, M, Fukuzawa, S, Ozawa, S, Inagaki, M, Sugioka, J, Okino, S, Ichikawa, S, Mohart, JM, Fairlamb, JE, Hutter, AJ, Gutierrez, FR, Zheng, J, Lesniak, DM, Gropler, RJ, Woodard, PK, Santana, C, Esteves, FP, Lerakis, S, Halkar, R, Narla, R, Santana, CA, Alvarez, A, Halkar, RK, Chen, S, Yao, Z, Ramrakhiani, S, Safadi, AH, Foltz, JM, Stricker, SL, Williams, AA, Grewal, KS, George, PB, Richards, DR, Calnon, DA, Bhama, A, Goetze, S, Wahl, RL, Elmquist, T, Mazzara, J, Hsu, BL, Moser, KW, Bateman, TM, Stoner, C, Case, JA, Matsumoto, N, Sato, Y, Yoda, S, Muromoto, M, Nalamolu, VRP, Patel, RN, Dias, JK, Kaminski, RJ, Kersey, TW, Robinson, VJB, Oaknin, JH, Shwartz, SC, Pagnanelli, RA, Coleman, RE, Borges-Neto, S, Cullom, SJ, Noble, GL, Masse, M, McGhie, AI, Friedman, JD, Devabhaktuni, M, Hickey, KT, Sciacca, RR, Giedd, KN, Johnson, U, Bokhari, S, Nemirovsky, D, Machac, J, Almeida, D, Kanayama, S, Satake, O, Kajinami, K, Hertenstein, GK, Volker, LL, Verdes, L, Folks, RD, Clements, IP, Mullan, BP, Breen, JF, McGregor, CG, Côté, C, Dumont, M, Lefebvre, J, Poirier, L, Lacourcière, Y, Gupta, R, Aqel, RA, Mehta, D, Clay, MA, Zoghbi, G, Hwang, K-H, Kim, J-H, Choe, W, Kim, N-B, Khateeb, R, Keefer, PM, Vedala, G, Mahajan, NM, Shetty, VS, Thekkott, DT, Hollander, GH, Greengart, AG, Shani, JS, Lichstein, EL, Raza, M, Panjrath, G, Meesala, M, Ghanbarinia, A, Jain, D, Seo, I, Del Priore, E, Almonte, A, Kappes, R, Fedida, A, Ong, K, Kritzman, JN, Dey, S, Corbett, JR, Ficaro, EP, Stowers, SA, Tomlinson, GC, Cunningham, MS, Guilarte, NM, Carrio, I, Lundbye, JB, Katten, D, Ahlberg, A, Boden, WE, Cyr, G, Paiesdana, A, and Murthy, DR
Published: 2005
Full Text: View/download PDF

6. Anatomic versus Physiologic Assessment of Coronary Artery Disease: Role of CFR, FFR, and PET Imaging in Revascularization Decision-Making

Author: Gould KL, Johnson NP, Bateman TM, Beanlands RS, Bengel FM, Bober R, CAMICI , PAOLO, Cerqueira MD, Chow BJW, Di Cali MF, Dorbala S, Gewirtz H, Gropler RJ, Kaufmann PA, Knaapen P, Knuuti J, Merhige ME, Rentrop KP, Ruddy TD, Schelbert HR, Shindler TH, Schwaiger M., Gould, Kl, Johnson, Np, Bateman, Tm, Beanlands, R, Bengel, Fm, Bober, R, Camici, Paolo, Cerqueira, Md, Chow, Bjw, Di Cali, Mf, Dorbala, S, Gewirtz, H, Gropler, Rj, Kaufmann, Pa, Knaapen, P, Knuuti, J, Merhige, Me, Rentrop, Kp, Ruddy, Td, Schelbert, Hr, Shindler, Th, and Schwaiger, M.
Published: 2013

7. Proceedings of SPIE - The International Society for Optical Engineering: Introduction

Author: Johnson, NP, Boardman, AD, and Ziolkowski, RW
Subjects: ComputingMilieux_GENERAL, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract: This PDF file contains the front matter associated with SPIE Proceedings Volume 8423, including the Title Page, Copyright information, Table of Contents, and the Conference Committee listing. © 2012 Copyright Society of Photo-Optical Instrumentation Engineers (SPIE).
Published: 2012

8. Management of Hydrosalpinges

Author: van Voorst, Sabine, Johnson, NP, and Obstetrics & Gynecology
Published: 2010

9. Awareness of substance abuse in orthopedic patients: a survey of orthopedic surgeons

Author: Hornung Ca, Schwartz Rh, Berg Ew, Johnson Np, and Phelps Gl
Subjects: Drug, Male, medicine.medical_specialty, Patients, Substance-Related Disorders, media_common.quotation_subject, Drug Prescriptions, Patient care, Benzodiazepines, Addiction medicine specialist, Surveys and Questionnaires, medicine, Humans, Psychiatry, media_common, Analgesics, business.industry, Chronic pain, Alcohol and drug, Professional Practice, General Medicine, Middle Aged, medicine.disease, Benzodiazepine abuse, Substance abuse, Alcoholism, Orthopedics, Orthopedic surgery, Education, Medical, Continuing, Female, business
Abstract: We surveyed 178 orthopedic physicians in the Washington, DC, area to ascertain the effect on patient care of previous education in the area of drug and alcohol issues. The return rate was 75%. Of the respondents, 99% were male, average age was 46.7 years (+/- 9.3), and average number of years in practice was 15.2 (+/- 9.6). A majority of respondents indicated that they did not have training in the abuse potential of analgesics (92 [69%]), characteristics of benzodiazepine abuse (77 [58%]), or when to seek the assistance of an addiction medicine specialist for patients with chronic pain (106 [80%]). Only 41 (31%) of the orthopedists indicated that they inquire about alcohol and drug use before prescribing opiates for more than a week. We offer suggestions for self-education for interested physicians.
Published: 1991

10. Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy

Author: Johnson, NP, primary, Bagrie, EM, additional, Coomarasamy, A, additional, Bhattacharya, S, additional, Shelling, AN, additional, Jessop, S, additional, Farquhar, C, additional, and Khan, KS, additional
Published: 2006
Full Text: View/download PDF

11. Techniques for surgical retrieval of sperm prior to ICSI for azoospermia

Author: Van Peperstraten, A, primary, Proctor, ML, additional, Johnson, NP, additional, and Philipson, G, additional
Published: 2006
Full Text: View/download PDF

12. Cost-effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding

Author: Brown, PM, primary, Farquhar, CM, additional, Lethaby, A, additional, Sadler, LC, additional, and Johnson, NP, additional
Published: 2006
Full Text: View/download PDF

13. Is ovarian surgery effective for androgenic symptoms of polycystic ovarian syndrome?

Author: Johnson, NP, primary and Wang, Kaye, additional
Published: 2003
Full Text: View/download PDF

14. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation

Author: Johnson, NP, primary, Mak, W, additional, and Sowter, MC, additional
Published: 2001
Full Text: View/download PDF

15. Techniques for surgical retrieval of sperm prior to ICSI for azoospermia

Author: Van Peperstraten, A, primary, Proctor, ML, additional, Johnson, NP, additional, and Philipson, G, additional
Published: 2001
Full Text: View/download PDF

16. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea

Author: Proctor, ML, primary, Farquhar, CM, additional, Sinclair, OJ, additional, and Johnson, NP, additional
Published: 1999
Full Text: View/download PDF

17. Prognostic value of late heart rate recovery after treadmill exercise.

Author: Johnson NP and Goldberger JJ
Published: 2012

18. Significance of asymptomatic bradycardia for subsequent pacemaker implantation and mortality in patients >60 years of age.

Author: Goldberger JJ, Johnson NP, and Gidea C
Published: 2011
Full Text: View/download PDF

19. Development of clinical-quality registries in Australia: the way forward.

Author: Evans SM, Scott IA, Johnson NP, Cameron PA, McNeil JJ, Evans, Sue M, Scott, Ian A, Johnson, Niall P, Cameron, Peter A, and McNeil, John J
Abstract: Australia is developing a national performance framework aimed at measuring health outcomes across the health system. Clinical registries provide a clinically credible means of monitoring health care processes and outcomes, yet only five Australian registries currently have national coverage. At a national level, clinical registry development should be prioritised to target conditions or procedures that are suspected of being associated with large variations in processes or outcomes of care and that impact significantly on health care costs and patient morbidity. Registries should also aim to capture information across care interfaces and to monitor the medium and long-term safety and effectiveness of specific devices, procedures and drugs. [ABSTRACT FROM AUTHOR]
Published: 2011
Full Text: View/download PDF

20. Partial volume correction incorporating Rb-82 positron range for quantitative myocardial perfusion PET based on systolic-diastolic activity ratios and phantom measurements.

Author: Johnson NP, Sdringola S, Gould KL, Johnson, Nils P, Sdringola, Stefano, and Gould, K Lance
Abstract: Background: Quantitative myocardial PET perfusion imaging requires partial volume corrections.Methods: Patients underwent ECG-gated, rest-dipyridamole, myocardial perfusion PET using Rb-82 decay corrected in Bq/cc for diastolic, systolic, and combined whole cycle ungated images. Diastolic partial volume correction relative to systole was determined from the systolic/diastolic activity ratio, systolic partial volume correction from phantom dimensions comparable to systolic LV wall thicknesses and whole heart cycle partial volume correction for ungated images from fractional systolic-diastolic duration for systolic and diastolic partial volume corrections.Results: For 264 PET perfusion images from 159 patients (105 rest-stress image pairs, 54 individual rest or stress images), average resting diastolic partial volume correction relative to systole was 1.14 ± 0.04, independent of heart rate and within ±1.8% of stress images (1.16 ± 0.04). Diastolic partial volume corrections combined with those for phantom dimensions comparable to systolic LV wall thickness gave an average whole heart cycle partial volume correction for ungated images of 1.23 for Rb-82 compared to 1.14 if positron range were negligible as for F-18.Conclusion: Quantitative myocardial PET perfusion imaging requires partial volume correction, herein demonstrated clinically from systolic/diastolic absolute activity ratios combined with phantom data accounting for Rb-82 positron range. [ABSTRACT FROM AUTHOR]
Published: 2011
Full Text: View/download PDF

21. Survey of Australasian clinicians' prior beliefs concerning lipiodol flushing as a treatment for infertility: a Bayesian study.

Author: Johnson NP, Fisher RA, Braunholtz DA, Gillett WR, and Lilford RJ
Published: 2006
Full Text: View/download PDF

22. After the FLUSH trial: a prospective observational study of lipiodol flushing as an innovative treatment for unexplained and endometriosis-related infertility.

Author: Brent K, Hadden WE, Weston-Webb M, and Johnson NP
Published: 2006
Full Text: View/download PDF

23. No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene.

Author: Johnson NP
Published: 2006
Full Text: View/download PDF

24. Drinking problems in nursing students.

Author: Marion LN, Fuller SG, Johnson NP, Michels PJ, and Diniz C
Published: 1996
Full Text: View/download PDF

25. Do men undergoing sterilizing cancer treatments have a fertile future?

Author: Naysmith, TE, Blake, DA, Harvey, VJ, Johnson, NP, Naysmith, T E, Blake, D A, Harvey, V J, and Johnson, N P
Abstract: This study was designed to assess the effect of cancer treatments on the natural and assisted reproductive potential of men. A cohort of men with cancer, in whom radiotherapy and/or chemotherapy was planned, were invited to participate. Twenty-two pre- and post-treatment semen samples were analysed. The reproductive potential of participants was assessed with respect to the current range of fertility treatment options available. Abnormal sperm concentrations were found in 27% of patients pre-treatment compared to 68% post-treatment following a mean latency of 20 months from treatment. Fifty-nine percent of patients experienced a clinically significant decrease in sperm, concentration following radiotherapy and/or chemotherapy; 23% developed azoospermia following treatment. Eighty-two percent of patients with testicular malignancy had oligo- or azoospermia post-treatment. Only one patient had a clinically significant reduction in the percentage of motile spermatozoa post-treatment. Cryopreservation of semen prior to treatment improved the fertility prospects of 55% of patients. Intracytoplasmic sperm injection (ICSI) enhanced the fertility prospects of a further 14%. In the absence of, or after depletion of, cryopreserved semen, ICSI could enhance the fertility prospects of 45% of patients. Fertilization has been achieved by ICSI using spermatozoa retrieved by testicular biopsy from an azoospermic testicular cancer survivor 8 years after chemotherapy. It was concluded that chemotherapy and/or radiotherapy may depress semen concentration to the extent of rendering a man infertile. The severity of the reduction in sperm concentration following treatment is unpredictable but likely to be most severe in those with testicular malignancy and those treated with radiotherapy or alkylating chemotherapy agents. Not all men are keen to undergo an appraisal of their post-treatment fertility potential, for reasons which are unclear. Improving awareness and education of patients concerning the effects of both cancer and cancer treatments on reproductive potential is essential. With the advent of ICSI, it is possible to offer a very reasonable chance of conception in all men with cancer who present for cryopreservation of semen prior to treatment in whom spermatozoa (even in very low concentrations) are present in the ejaculate. [ABSTRACT FROM AUTHOR]
Published: 1998
Full Text: View/download PDF

26. Letter of Intent by the Solenoidal Detector Collaboration to construct and operate a detector at the Superconducting Super Collider

Author: SDC Collaboration, Trilling, GH, Berger, EL, Blair, RE, Dawson, JW, Ekenberg, TL, Derrick, M, Fields, TH, Guarino, V, Hagstrom, RT, Hill, NF, Job, P, Kirk, TBW, May, EN, Nasiatka, J, Nodulman, LJ, Price, LE, Proudfoot, J, Spinka, HM, Talaga, RL, Trost, HJ, Underwood, DG, Wagner, RG, Wicklund, AB, Wu, MM, Johns, KA, Cui, Hua-chuan, Gao, Wen-xiu, Huang, De-qiang, Li, Wei-guo, Mao, Hui-shun, Ni, Hui-ling, Qi, Na-ding, Wang, Tai-jie, Yan, Wu-guang, Ye, Ming-han, Zhao, Wei-ren, Zheng, Liu-sheng, Zhou, Yue-hua, Ming, He Yu, Xi, Lai Chu, Tao, Liu Hong, Qiu, Liu Song, Qiao, Lou Bing, Xiang, Yang Ji, De, Yao Shu, Ju, Zhang Re, Behrends, S, Bensinger, JR, Blocker, C, Kesten, P, Kirsch, L, Povinec, P, Strmen, P, Foster, B, Heath, GP, Cutts, D, Gao, GS, Partridge, R, Alexa, A, Horoi, M, Pantea, D, Pentia, M, Petrascu, C, Weinstein, AJ, Gunion, JF, Pellett, D, Mani, S, Lankford, A, Arisaka, K, Bengtsson, HU, Buchanan, C, Chrisman, D, Cline, D, Hauser, J, Muller, T, Park, J, Roberts, D, Slater, W, Ellison, J, Wimpenny, SJ, Sivertz, M, Thomas, D, DeWitt, J, Dorfan, D, Heusch, C, Hubbard, B, Hutchinson, D, Litke, AL, Lockman, WS, Nilsson, W, O'Shaughnessy, K, Pitzl, D, Rowe, W, Sadrozinski, H, Seiden, A, Spencer, E, Armitage, J, Dixit, MS, Estabrooks, P, Godfrey, S, Losty, M, Mes, H, Oakham, G, O'Neille, M, Kawai, H, Campagneri, C, Contreras, M, Eno, S, Frisch, H, Gross-Pilcher, C, Miller, M, Rosenberg, L, Sanders, H, Shochet, M, Sullivan, G, Baranko, GJ, Cheung, HWK, Cumalat, JP, Erdos, E, Ford, WT, Nauenberg, U, Rankin, P, Schultz, G, Smith, JG, Astakhov, VI, Batyunya, BV, Bischoff, A, Budagov, YA, Chuenko, AM, Dokshin, AI, Finger, M, Gerasimov, SB, Golovatyuk, VM, Gotra, Yu N, Gusar, Yu S, Guzik, Z, Khubua, DI, Ilyin, Yu V, Kashigin, SV, Kharzheev, YN, Kolpakov, IF, Kovalenko, AD, Levchanovsky, FV, Lomakin, YF, Malakhov, AI, Matyushevsky, EA, Omelyanenko, AA, Pakhmutov, Yu S, Panebratsev, YA, Puzynin, IV, Semenov, AA, Senner, AE, Shabunov, AV, Sidorov, VT, Sinaev, AN, Sisakian, AN, Smirnov, V, Spassov, T, Tsyganov, EN, Tyapkin, IA, Vasilev, LA, Velev, GV, Vinogradov, VB, Vodopyanov, AS, Vrba, V, Zanevsky, Yu V, Zhuravlev, NI, Zimin, NI, Zinchenko, AI, Goshaw, AT, Oh, SH, Phillips, TJ, Robertson, WJ, Simpkins, JD, Walker, WD, Amatuni, AC, Vartapetian, GA, Areti, VH, Atac, M, Barsotti, E, Bartoszek, L, Baumbaugh, AE, Beretvas, A, Bernstein, R, Binkley, M, Bross, AD, Clark, AG, Cooper, JW, Denby, BH, Denisenko, KG, Denisenko, NL, Droege, T, Eartly, DP, Elias, JE, Fast, RW, Finley, D, Foster, GW, Freeman, J, Gaines, I, Gourlay, SA, Green, DR, Grimson, J, Grozis, C, Hahn, SR, Harris, RM, Hoff, J, Huth, J, Hylen, J, Kephart, RD, Kilmer, J, Krebs, HJ, Kuzminski, J, Lee, A, Limon, PJ, Martin, PS, Mukerjee, A, Nash, T, Newman-Holmes, C, Para, A, Patrick, J, Plunkett, R, Schmidt, EE, Segler, SL, Stanek, RP, Srefanik, A, Stredde, HJ, Tkaczyk, S, Vidal, R, Wagner, RL, Wands, RH, Yarema, R, Yeh, GP, Yoh, J, Zimmerman, T, Field, R, Harmon, J, Walker, J, Corden, M, Hagopian, V, Johnson, K, Wahl, H, Kawaguchi, M, Yoshida, H, Dvornik, AM, Maksimenko, NB, Brandenburg, G, Feldman, G, Franklin, M, Geer, S, Konigsberg, J, Oliver, J, Sadowski, E, Schlabach, P, Wilson, R, Kenney, C, Parker, S, Chiba, Y, Ohsugi, T, Asai, M, Shioden, M, Goldberg, H, Margulies, S, Solomon, J, Downing, R, Errede, S, Gautier, A, Haney, M, Holloway, L, Karliner, I, Liss, A, O'Halloran, T, Thaler, J, Sheldon, P, Simaitis, V, Wiss, J, Blockus, D, Brabson, B, Dzierba, A, Foster, R, Hanson, G, Lou, X, Luehring, F, Martin, B, Ogren, H, Rust, D, Wente, E, Hauptman, J, Bagger, JA, Barnett, BA, Blumenfeld, BJ, Fisher, PH, Matthews, JAJ, Abe, F, Amako, K, Arai, Y, Doi, Y, Fujii, H, Fukui, Y, Haruyama, T, Ikeda, H, Inaba, S, Inagaki, T, Iwasaki, H, Kabe, S, Kanematsu, N, Kanzaki, J, Kondo, T, Maki, A, Manabe, A, Mishina, M, Noumachi, M, Odaka, S, Ogawa, K, Ohska, TK, Sakai, Y, Sakamoto, H, Sasaki, O, Shinkawa, T, Takaiwa, Y, Terada, S, Tsuboyama, T, Tsukada, K, Ujiie, N, Unno, Y, Watase, Y, Yamamoto, A, Yasu, Y, Krivan, F, Seman, M, Spalek, J, Kikuchi, R, Miyake, K, Abrams, GS, Barbaro-Galtieri, A, Barnett, RM, Cahn, RN, Corradi, CA, Eberhard, PH, Einsweiler, K, Edwards, WR, Ely, R, Gilchriese, MGD, Groom, DE, Haber, C, Hearty, C, Hinchliffe, I, Hoff, M, Jared, R, Kadel, RW, Kadyk, JA, Kleinfelder, S, Levi, ME, Lim, A, Loken, SC, Madden, N, Minamihara, YY, Milgrome, O, Millaud, J, Moore, TL, Nygren, DR, Palounek, APT, Pope, WL, Pripstein, M, Rasson, J, Shapiro, M, Shuman, D, Spieler, HG, Stone, R, Strovink, M, Thur, W, Weidenbach, RC, Wenzel, WA, Ziock, H, Bailey, J, Beck, GA, Dainton, JB, Gabathuler, E, Maxfield, SJ, Smith, G, Baden, AR, Ball, AH, Chang, CY, Fong, DG, Goodman, JA, Hadley, NJ, Jawahery, A, Kellogg, RG, Kunori, S, Skuja, A, Zorn, GT, Ragan, K, Stairs, DG, Amidei, D, Ball, RC, Campbell, M, Chapman, J, De, K, Derwent, P, Gustafson, HR, Hashim, K, Hong, S, Jones, LW, Kim, SB, Longo, MJ, Mann, J, Marcin, MR, Neal, HA, Nitz, D, Roe, BP, Snow, G, Thun, R, Wu, D, Zhang, S, Border, P, Courant, H, Gray, R, Heller, K, Kubota, Y, Marshak, M, Peterson, E, Poling, R, Ruddick, K, Kulchitsky, JA, Moroz, LG, Moore, D, Summers, D, Nakamura, T, Nakamura, M, Niwa, K, Miyano, K, Miyata, H, Bishop, J, Biswas, N, Cason, N, Godfrey, J, Kenney, VP, Piekarz, J, Ruchti, R, Shephard, W, Alley, G, Alsmiller, RG, Alsmiller, FS, Fu, CY, Glover, CW, Mahall, J, Ryan, T, Vandergriff, D, Byslma, B, Durkin, LS, Ling, TY, Park, SK, Romanowski, TA, Tamura, N, Okusawa, T, Takahashi, T, Teramoto, Y, Yoshida, T, Nagashima, Y, Sugimoto, S, Bibby, J, Cashmore, R, Harnew, N, Nickerson, R, Williams, W, Gladney, L, Hollebeek, RJ, Newcomer, M, Van Berg, R, Williams, HH, Armstrong, TA, Hartman, KW, Hasan, A, Heppelmann, SF, Lewis, RA, Minor, ED, Oh, BY, Smith, GA, Toothacker, WS, Whitmore, J, Zhang, Y, Amendolia, R, Bedeschi, F, Bellettini, G, Galeotti, S, Grassman, H, Mangano, ML, Menzione, A, Pauletta, G, Passuello, D, Punzi, G, Ristori, L, Engels, EE, Humanic, T, Shepard, PF, Barnes, VE, Garfinkel, AF, Koltick, DS, Laasanen, AT, McIlwain, R, Miller, DH, Shibata, E, Shipsey, IP, Adams, D, Ahmad, S, Bonner, B, Corcoran, M, Miettinen, H, Mutchler, G, Roberts, J, Skeens, J, Bodek, A, Kanda, S, Lobkowicz, F, Sill, A, Slattery, P, Thorndike, EH, Appolinari, G, Giokaris, N, Goulianos, K, Melese, P, Rusack, R, Vacchi, A, White, S, Devlin, T, Watts, T, Edwards, M, Gee, N, Grayer, G, Bonamy, P, Ernwein, J, Hubbard, R, Le Du, P, Pansart, J -P, Rondeaux, F, Murakami, A, Kobayashi, S, Masuda, K, Tsenov, RV, Iordanov, AB, Bintinger, D, Coupal, D, Fry, A, Johnstad, H, Siegrist, J, Turcotte, M, Aliev, Sh, Kan, S, Khaneles, A, Pak, A, Surin, E, Yuldashev, B, Alimov, M, Gulamov, K, Kaprior, V, Myalkovsky, V, Turdaliev, K, Yuldashev, A, Amaglobeli, NS, Chiladze, BG, Hubua, DI, Salukvadze, RG, Grunhaus, J, Heifetz, R, Levy, A, Barasch, E, Bowcock, TJV, Huson, FR, McIntyre, PM, White, J T, Cantrell, CD, Chaney, RC, Fenyves, EJ, Hammack, H, Orgeron, J, Lowery, WB, Johnson, NP, Higuchi, M, Hoshi, Y, Abe, K, Hasegawa, K, Yuta, H, Kato, S, Nishikawa, K, Homma, S, Miyachi, T, Kaneyuki, K, Tanimori, T, Watanabe, Y, Chiba, M, Hamatsu, R, Hirose, T, Emura, T, Takahashi, K, Bailey, DC, Luste, GJ, Martin, JF, Orr, RS, Prentice, JD, Sinervo, P, Yoon, TS, Fujiwara, I, Funayama, Y, Hara, K, Iinuma, T, Kaneko, T, Kim, S, Kondo, K, Miyashita, S, Morita, Y, Nakano, I, Takano, M, Takikawa, K, Yasuoka, K, Asano, Y, Mori, S, Takada, Y, Kafka, T, Mann, WA, Milburn, RH, Napier, A, Sliwa, K, Lu, B, Mo, LW, Nunamaker, TA, Piilonen, LE, Daigo, M, Davisson, RJ, Liang, G, Lubatti, HJ, Wilkes, RJ, Zhao, T, Bellinger, J, Carlsmith, D, Cherwinka, J, Erwin, A, Feyzi, F, Foudas, C, Lackey, J, Loveless, R, Ott, G, Reeder, DD, Smith, W, Wendt, C, Wu, SL, Frisken, WR, Hasell, D, Koniuk, R, Courtney, W, Fisher, S, Elam, A, Poole, E, Caprio, C, Kapcio, P, Buddle, B, Gerace, T, Arens, JF, Jernigan, JG, Atlas, G, Barkan, Ol, Collins, T, Kramer, G, Pfeiffer, C, Wheeler, B, Wolfe, D, Worley, S, Anderson, EJ, Petroff, MD, Brown, J, Dittert, L, McGinley, W, Nunez, A, Riddle, M, Klokow, D, VanderHave, L, Shapiro, SL, Burke, MA, Einolf, C W, Hackworth, DT, Marschik, D, Scherbarth, DW, Swensrud, RL, Toms, JM, SDC Collaboration, Trilling, GH, Berger, EL, Blair, RE, Dawson, JW, Ekenberg, TL, Derrick, M, Fields, TH, Guarino, V, Hagstrom, RT, Hill, NF, Job, P, Kirk, TBW, May, EN, Nasiatka, J, Nodulman, LJ, Price, LE, Proudfoot, J, Spinka, HM, Talaga, RL, Trost, HJ, Underwood, DG, Wagner, RG, Wicklund, AB, Wu, MM, Johns, KA, Cui, Hua-chuan, Gao, Wen-xiu, Huang, De-qiang, Li, Wei-guo, Mao, Hui-shun, Ni, Hui-ling, Qi, Na-ding, Wang, Tai-jie, Yan, Wu-guang, Ye, Ming-han, Zhao, Wei-ren, Zheng, Liu-sheng, Zhou, Yue-hua, Ming, He Yu, Xi, Lai Chu, Tao, Liu Hong, Qiu, Liu Song, Qiao, Lou Bing, Xiang, Yang Ji, De, Yao Shu, Ju, Zhang Re, Behrends, S, Bensinger, JR, Blocker, C, Kesten, P, Kirsch, L, Povinec, P, Strmen, P, Foster, B, Heath, GP, Cutts, D, Gao, GS, Partridge, R, Alexa, A, Horoi, M, Pantea, D, Pentia, M, Petrascu, C, Weinstein, AJ, Gunion, JF, Pellett, D, Mani, S, Lankford, A, Arisaka, K, Bengtsson, HU, Buchanan, C, Chrisman, D, Cline, D, Hauser, J, Muller, T, Park, J, Roberts, D, Slater, W, Ellison, J, Wimpenny, SJ, Sivertz, M, Thomas, D, DeWitt, J, Dorfan, D, Heusch, C, Hubbard, B, Hutchinson, D, Litke, AL, Lockman, WS, Nilsson, W, O'Shaughnessy, K, Pitzl, D, Rowe, W, Sadrozinski, H, Seiden, A, Spencer, E, Armitage, J, Dixit, MS, Estabrooks, P, Godfrey, S, Losty, M, Mes, H, Oakham, G, O'Neille, M, Kawai, H, Campagneri, C, Contreras, M, Eno, S, Frisch, H, Gross-Pilcher, C, Miller, M, Rosenberg, L, Sanders, H, Shochet, M, Sullivan, G, Baranko, GJ, Cheung, HWK, Cumalat, JP, Erdos, E, Ford, WT, Nauenberg, U, Rankin, P, Schultz, G, Smith, JG, Astakhov, VI, Batyunya, BV, Bischoff, A, Budagov, YA, Chuenko, AM, Dokshin, AI, Finger, M, Gerasimov, SB, Golovatyuk, VM, Gotra, Yu N, Gusar, Yu S, Guzik, Z, Khubua, DI, Ilyin, Yu V, Kashigin, SV, Kharzheev, YN, Kolpakov, IF, Kovalenko, AD, Levchanovsky, FV, Lomakin, YF, Malakhov, AI, Matyushevsky, EA, Omelyanenko, AA, Pakhmutov, Yu S, Panebratsev, YA, Puzynin, IV, Semenov, AA, Senner, AE, Shabunov, AV, Sidorov, VT, Sinaev, AN, Sisakian, AN, Smirnov, V, Spassov, T, Tsyganov, EN, Tyapkin, IA, Vasilev, LA, Velev, GV, Vinogradov, VB, Vodopyanov, AS, Vrba, V, Zanevsky, Yu V, Zhuravlev, NI, Zimin, NI, Zinchenko, AI, Goshaw, AT, Oh, SH, Phillips, TJ, Robertson, WJ, Simpkins, JD, Walker, WD, Amatuni, AC, Vartapetian, GA, Areti, VH, Atac, M, Barsotti, E, Bartoszek, L, Baumbaugh, AE, Beretvas, A, Bernstein, R, Binkley, M, Bross, AD, Clark, AG, Cooper, JW, Denby, BH, Denisenko, KG, Denisenko, NL, Droege, T, Eartly, DP, Elias, JE, Fast, RW, Finley, D, Foster, GW, Freeman, J, Gaines, I, Gourlay, SA, Green, DR, Grimson, J, Grozis, C, Hahn, SR, Harris, RM, Hoff, J, Huth, J, Hylen, J, Kephart, RD, Kilmer, J, Krebs, HJ, Kuzminski, J, Lee, A, Limon, PJ, Martin, PS, Mukerjee, A, Nash, T, Newman-Holmes, C, Para, A, Patrick, J, Plunkett, R, Schmidt, EE, Segler, SL, Stanek, RP, Srefanik, A, Stredde, HJ, Tkaczyk, S, Vidal, R, Wagner, RL, Wands, RH, Yarema, R, Yeh, GP, Yoh, J, Zimmerman, T, Field, R, Harmon, J, Walker, J, Corden, M, Hagopian, V, Johnson, K, Wahl, H, Kawaguchi, M, Yoshida, H, Dvornik, AM, Maksimenko, NB, Brandenburg, G, Feldman, G, Franklin, M, Geer, S, Konigsberg, J, Oliver, J, Sadowski, E, Schlabach, P, Wilson, R, Kenney, C, Parker, S, Chiba, Y, Ohsugi, T, Asai, M, Shioden, M, Goldberg, H, Margulies, S, Solomon, J, Downing, R, Errede, S, Gautier, A, Haney, M, Holloway, L, Karliner, I, Liss, A, O'Halloran, T, Thaler, J, Sheldon, P, Simaitis, V, Wiss, J, Blockus, D, Brabson, B, Dzierba, A, Foster, R, Hanson, G, Lou, X, Luehring, F, Martin, B, Ogren, H, Rust, D, Wente, E, Hauptman, J, Bagger, JA, Barnett, BA, Blumenfeld, BJ, Fisher, PH, Matthews, JAJ, Abe, F, Amako, K, Arai, Y, Doi, Y, Fujii, H, Fukui, Y, Haruyama, T, Ikeda, H, Inaba, S, Inagaki, T, Iwasaki, H, Kabe, S, Kanematsu, N, Kanzaki, J, Kondo, T, Maki, A, Manabe, A, Mishina, M, Noumachi, M, Odaka, S, Ogawa, K, Ohska, TK, Sakai, Y, Sakamoto, H, Sasaki, O, Shinkawa, T, Takaiwa, Y, Terada, S, Tsuboyama, T, Tsukada, K, Ujiie, N, Unno, Y, Watase, Y, Yamamoto, A, Yasu, Y, Krivan, F, Seman, M, Spalek, J, Kikuchi, R, Miyake, K, Abrams, GS, Barbaro-Galtieri, A, Barnett, RM, Cahn, RN, Corradi, CA, Eberhard, PH, Einsweiler, K, Edwards, WR, Ely, R, Gilchriese, MGD, Groom, DE, Haber, C, Hearty, C, Hinchliffe, I, Hoff, M, Jared, R, Kadel, RW, Kadyk, JA, Kleinfelder, S, Levi, ME, Lim, A, Loken, SC, Madden, N, Minamihara, YY, Milgrome, O, Millaud, J, Moore, TL, Nygren, DR, Palounek, APT, Pope, WL, Pripstein, M, Rasson, J, Shapiro, M, Shuman, D, Spieler, HG, Stone, R, Strovink, M, Thur, W, Weidenbach, RC, Wenzel, WA, Ziock, H, Bailey, J, Beck, GA, Dainton, JB, Gabathuler, E, Maxfield, SJ, Smith, G, Baden, AR, Ball, AH, Chang, CY, Fong, DG, Goodman, JA, Hadley, NJ, Jawahery, A, Kellogg, RG, Kunori, S, Skuja, A, Zorn, GT, Ragan, K, Stairs, DG, Amidei, D, Ball, RC, Campbell, M, Chapman, J, De, K, Derwent, P, Gustafson, HR, Hashim, K, Hong, S, Jones, LW, Kim, SB, Longo, MJ, Mann, J, Marcin, MR, Neal, HA, Nitz, D, Roe, BP, Snow, G, Thun, R, Wu, D, Zhang, S, Border, P, Courant, H, Gray, R, Heller, K, Kubota, Y, Marshak, M, Peterson, E, Poling, R, Ruddick, K, Kulchitsky, JA, Moroz, LG, Moore, D, Summers, D, Nakamura, T, Nakamura, M, Niwa, K, Miyano, K, Miyata, H, Bishop, J, Biswas, N, Cason, N, Godfrey, J, Kenney, VP, Piekarz, J, Ruchti, R, Shephard, W, Alley, G, Alsmiller, RG, Alsmiller, FS, Fu, CY, Glover, CW, Mahall, J, Ryan, T, Vandergriff, D, Byslma, B, Durkin, LS, Ling, TY, Park, SK, Romanowski, TA, Tamura, N, Okusawa, T, Takahashi, T, Teramoto, Y, Yoshida, T, Nagashima, Y, Sugimoto, S, Bibby, J, Cashmore, R, Harnew, N, Nickerson, R, Williams, W, Gladney, L, Hollebeek, RJ, Newcomer, M, Van Berg, R, Williams, HH, Armstrong, TA, Hartman, KW, Hasan, A, Heppelmann, SF, Lewis, RA, Minor, ED, Oh, BY, Smith, GA, Toothacker, WS, Whitmore, J, Zhang, Y, Amendolia, R, Bedeschi, F, Bellettini, G, Galeotti, S, Grassman, H, Mangano, ML, Menzione, A, Pauletta, G, Passuello, D, Punzi, G, Ristori, L, Engels, EE, Humanic, T, Shepard, PF, Barnes, VE, Garfinkel, AF, Koltick, DS, Laasanen, AT, McIlwain, R, Miller, DH, Shibata, E, Shipsey, IP, Adams, D, Ahmad, S, Bonner, B, Corcoran, M, Miettinen, H, Mutchler, G, Roberts, J, Skeens, J, Bodek, A, Kanda, S, Lobkowicz, F, Sill, A, Slattery, P, Thorndike, EH, Appolinari, G, Giokaris, N, Goulianos, K, Melese, P, Rusack, R, Vacchi, A, White, S, Devlin, T, Watts, T, Edwards, M, Gee, N, Grayer, G, Bonamy, P, Ernwein, J, Hubbard, R, Le Du, P, Pansart, J -P, Rondeaux, F, Murakami, A, Kobayashi, S, Masuda, K, Tsenov, RV, Iordanov, AB, Bintinger, D, Coupal, D, Fry, A, Johnstad, H, Siegrist, J, Turcotte, M, Aliev, Sh, Kan, S, Khaneles, A, Pak, A, Surin, E, Yuldashev, B, Alimov, M, Gulamov, K, Kaprior, V, Myalkovsky, V, Turdaliev, K, Yuldashev, A, Amaglobeli, NS, Chiladze, BG, Hubua, DI, Salukvadze, RG, Grunhaus, J, Heifetz, R, Levy, A, Barasch, E, Bowcock, TJV, Huson, FR, McIntyre, PM, White, J T, Cantrell, CD, Chaney, RC, Fenyves, EJ, Hammack, H, Orgeron, J, Lowery, WB, Johnson, NP, Higuchi, M, Hoshi, Y, Abe, K, Hasegawa, K, Yuta, H, Kato, S, Nishikawa, K, Homma, S, Miyachi, T, Kaneyuki, K, Tanimori, T, Watanabe, Y, Chiba, M, Hamatsu, R, Hirose, T, Emura, T, Takahashi, K, Bailey, DC, Luste, GJ, Martin, JF, Orr, RS, Prentice, JD, Sinervo, P, Yoon, TS, Fujiwara, I, Funayama, Y, Hara, K, Iinuma, T, Kaneko, T, Kim, S, Kondo, K, Miyashita, S, Morita, Y, Nakano, I, Takano, M, Takikawa, K, Yasuoka, K, Asano, Y, Mori, S, Takada, Y, Kafka, T, Mann, WA, Milburn, RH, Napier, A, Sliwa, K, Lu, B, Mo, LW, Nunamaker, TA, Piilonen, LE, Daigo, M, Davisson, RJ, Liang, G, Lubatti, HJ, Wilkes, RJ, Zhao, T, Bellinger, J, Carlsmith, D, Cherwinka, J, Erwin, A, Feyzi, F, Foudas, C, Lackey, J, Loveless, R, Ott, G, Reeder, DD, Smith, W, Wendt, C, Wu, SL, Frisken, WR, Hasell, D, Koniuk, R, Courtney, W, Fisher, S, Elam, A, Poole, E, Caprio, C, Kapcio, P, Buddle, B, Gerace, T, Arens, JF, Jernigan, JG, Atlas, G, Barkan, Ol, Collins, T, Kramer, G, Pfeiffer, C, Wheeler, B, Wolfe, D, Worley, S, Anderson, EJ, Petroff, MD, Brown, J, Dittert, L, McGinley, W, Nunez, A, Riddle, M, Klokow, D, VanderHave, L, Shapiro, SL, Burke, MA, Einolf, C W, Hackworth, DT, Marschik, D, Scherbarth, DW, Swensrud, RL, and Toms, JM

27. Expression of interest by the Solenoidal Detector Collaboration to construct and operate a detector at the Superconducting Super Collider

Author: SDC Collaboration, Trilling, GH, Berger, EL, Blair, RE, Dawson, JW, Derrick, M, Fields, TH, Hagstrom, RT, Hill, NF, Job, P, Kirk, TB, May, EN, Nodulman, LJ, Price, LE, Proudfoot, J, Spinka, HM, Talaga, RL, Trost, HJ, Underwood, DG, Wagner, RG, Wicklund, A B, Johns, KA, Behrends, S, Bensinger, JR, Blocker, C, Kesten, P, Kirsch, L, Povinec, P, Strmen, P, Foster, B, Heath, GP, Cutts, D, Partridge, R, Pellett, D, Arisaka, K, Chrisman, D, Cline, D, Park, J, Roberts, D, Slater, W, Yamamoto, H, Ellison, J, Wimpenny, SJ, Sivertz, M, Thomas, D, Dorfan, D, Heusch, C, Hubbard, B, Litke, AL, Lockman, WS, Pitzl, D, Sadrozinski, H, Seiden, A, Kawai, H, Campagneri, C, Eno, S, Frisch, H, Gross-Pilcher, C, Miller, M, Rosenberg, L, Shochet, M, Sullivan, G, Baranko, GJ, Carr, J, Cheung, HWK, Cumalat, JP, Ford, WT, Nauenberg, U, Rankin, P, Smith, JG, Astakhov, VI, Batyunya, BV, Bischoff, A, Budagov, YA, Denisenko, KG, Denisenko, NL, Gerasimov, SB, Golovatyuk, VM, Guzik, Z, Khubua, DI, Kadyrov, R, Kharzjeev, YN, Kolpakov, IF, Kovalenko, AD, Levchanovsky, FV, Lomakin, YF, Malakhov, AI, Omelyanenko, AA, Panebratsev, YA, Puzynin, IV, Semenov, AA, Senner, AE, Sidorov, VT, Sinaev, AN, Sisakian, AN, Smirnov, V, Spassof, T, Tsyganov, EN, Tyapkin, IA, Velev, GV, Vinogradov, VB, Vodopyanov, AS, Brba, V, Zanevsky, Yu V, Zhuravlev, NI, Zimin, NI, Zinchenko, AI, Fortney, LR, Goshaw, AT, Kowald, W, Oh, SH, Robertson, WJ, Walker, WD, Amatuni, AC, Vartapetian, GA, Amidei, D, Atac, M, Baumbaugh, AE, Beretvas, A, Bernstein, R, Binkley, M, Bross, AD, Clark, AG, Cooper, JW, Eartly, DP, Elias, JE, Fast, R W, Finley, D, Foster, G W, Freeman, J, Gaines, I, Gourlay, SA, Green, DR, Hahn, SR, Harris, RM, Hauser, J, Huth, J, Kephart, RD, Kuzminski, J, Martin, PS, Mishina, M, Mukerjee, A, Nash, T, Newman-Holmes, C, Para, A, Patrick, J, Plunkett, R, Schmidt, EE, Segler, SL, Tkaczyk, S, Vidal, R, Wagner, RL, Yeh, GP, Yoh, J, Field, R, Harmon, J, Walker, J, Corden, M, Hagopian, V, Johnson, K, Wahl, H, Kawaguchi, M, Yoshida, H, Dvornik, AM, Maksimenko, NB, Brandenburg, G, Feldman, G, Franklin, M, Geer, S, Konigsberg, J, Oliver, J, Phillips, T, Wilson, R, Kenney, C, Parker, S, Chiba, Y, Ohsugi, T, Asai, M, Shioden, M, Goldberg, H, Margulies, S, Solomon, J, Downing, R, Errede, S, Gautier, A, Haney, M, Holloway, L, Karliner, I, Liss, A, O'Halloran, T, Thaler, J, Sheldon, P, Simaitis, V, Wiss, J, Blockus, D, Brabson, B, Dzierba, A, Hanson, G, Lou, X, Ogren, H, Rust, D, Hauptman, J, Bagger, JA, Barnett, BA, Blumenfeld, BJ, Fisher, PH, Matthews, JAJ, Abe, F, Amako, K, Arai, Y, Doi, Y, Fujii, H, Fukui, Y, Haruyama, T, Ikeda, H, Ikeda, M, Inaba, S, Inagaki, T, Iwasaki, H, Kabe, S, Kanzaki, J, Kim, SK, Kondo, T, Maki, A, Manabe, A, Noumachi, M, Odaka, S, Ogawa, K, Sakai, Y, Sakamoto, H, Shinkawa, T, Takaiwa, Y, Terada, S, Tsuboyama, T, Tsukada, K, Ujiie, N, Unno, Y, Watase, Y, Yamamoto, A, Yasu, Y, Krivan, F, Seman, M, Spalek, J, Kikuchi, R, Miyake, K, Abrams, GS, Barbaro-Galtieri, A, Barnett, RM, Cahn, RN, Eberhard, PH, Einsweiler, K, Ely, R, Gilchriese, MGD, Groom, DE, Haber, C, Hearty, C, Hinchliffe, I, Kadel, RW, Kadyk, JA, Levi, ME, Limon, PJ, Loken, SC, Nygren, DR, Palounek, APT, Pripstein, M, Shapiro, M, Siegrist, JL, Spieler, HG, Strovink, M, Wang, EM, Wenzel, WA, Bailey, J, Beck, GA, Dainton, JB, Gabathuler, E, Maxfield, SJ, Baden, AR, Ball, AH, Chang, CY, Fong, DG, Goodman, JA, Hadley, NJ, Jawahery, A, Kellogg, RG, Kunori, S, Skuja, A, Zorn, GT, Ball, RC, Campbell, M, Chapman, J, Gustafson, HR, Hong, S, Jones, LW, Longo, MJ, Marcin, MR, Neal, HA, Nitz, D, Roe, BP, Snow, G, Thun, R, Border, P, Courant, H, Heller, K, Kubota, Y, Marshak, M, Peterson, E, Poling, R, Ruddick, K, Kulchitsky, JA, Moroz, LG, Moore, D, Summers, D, Nakamura, T, Nakamura, M, Niwa, K, Miyano, K, Miyata, H, Bishop, J, Biswas, N, Cason, N, Godfrey, J, Kenney, VP, Piekarz, J, Ruchti, R, Shephard, W, Alley, G, Alsmiller, RG, Alsmiller, FS, Fu, CY, Glover, CW, Vandergriff, D, Byslma, B, Durkin, LS, Ling, TY, Park, SK, Romanowski, TA, Tamura, N, Okusawa, T, Takahashi, T, Teramoto, Y, Yoshida, T, Nagashima, Y, Sugimoto, S, Cashmore, R, Harnew, N, Nickerson, R, Weidberg, A, Williams, W, Gladney, L, Hollebeek, RJ, Newcomer, M, Ragan, KJ, Sinervo, PK, Williams, HH, Armstrong, TA, Hartman, KW, Hasan, A, Heppelmann, SF, Lewis, RA, Minor, ED, Oh, BY, Smith, GA, Toothacker, WS, Whitmore, J, Amendolia, R, Bedeschi, F, Bellettini, G, Galeotti, S, Grassman, H, Mangano, ML, Menzione, A, Pauletta, G, Passuello, D, Punzi, G, Ristori, L, Engels, EE, Humanic, T, Mani, S, Shepard, PF, Barnes, VE, Garfinkel, AF, Koltick, DS, Laasanen, AT, McIlwain, R, Miller, DH, Shibata, E, Shipsey, IP, Adams, D, Ahmad, S, Bonner, B, Corcoran, M, Miettinen, H, Mutchler, G, Roberts, J, Skeens, J, Bodek, A, Lobkowicz, F, Sill, A, Slattery, P, Thorndike, EH, Giodaris, N, Goulianos, K, Melese, P, Rusack, R, White, S, Devlin, T, Watts, T, Gee, N, Harvey, JA, Murakami, A, Kobayashi, S, Masuda, K, Tsenov, RV, Iordanov, AB, Lankford, A, Bintinger, D, Johnstad, H, Aliev, Sh, Alimov, M, Gulamov, K, Kan, S, Kaprior, V, Khaneles, A, Myalkovsky, V, Pak, A, Surlin, E, Turdaliev, K, Yuldashev, A, Yuldashev, B, Amaglobeli, NS, Chiladze, BG, Hubua, DI, Salukvadze, RG, McIntyre, PM, Bowcock, TJV, Huson, FR, White, J T, Chaney, RC, Fenyves, EJ, Hammack, H, Orgeron, J, Lowery, WB, Johnson, NP, Higuchi, M, Hoshi, Y, Abe, K, Hasegawa, K, Yuta, H, Kato, S, Nishikawa, K, Homma, S, Miyachi, T, Watanabe, Y, Tanimori, T, Chiba, M, Hamatsu, R, Hirose, T, Kitamura, S, Emura, T, Takahashi, K, Funayama, Y, Hara, K, Kanda, S, Kaneko, T, Kim, S, Kondo, K, Mimashi, T, Miyashita, S, Morita, Y, Nakano, I, Sakurabata, H, Takikawa, K, Yasuoka, K, Asano, Y, Mori, S, Takada, Y, Kafka, T, Mann, WA, Milburn, RH, Napier, A, Sliwa, K, Lu, B, Mo, LW, Piilonen, LE, Daigo, M, Davisson, RJ, Liang, G, Lubatti, HJ, Wilkes, RJ, Zhao, T, Bellinger, J, Carlsmith, D, Erwin, A, Foudas, C, Handler, R, Loveless, R, Ott, G, Reeder, DD, Smith, W, Wendt, C, Wu, SL, SDC Collaboration, Trilling, GH, Berger, EL, Blair, RE, Dawson, JW, Derrick, M, Fields, TH, Hagstrom, RT, Hill, NF, Job, P, Kirk, TB, May, EN, Nodulman, LJ, Price, LE, Proudfoot, J, Spinka, HM, Talaga, RL, Trost, HJ, Underwood, DG, Wagner, RG, Wicklund, A B, Johns, KA, Behrends, S, Bensinger, JR, Blocker, C, Kesten, P, Kirsch, L, Povinec, P, Strmen, P, Foster, B, Heath, GP, Cutts, D, Partridge, R, Pellett, D, Arisaka, K, Chrisman, D, Cline, D, Park, J, Roberts, D, Slater, W, Yamamoto, H, Ellison, J, Wimpenny, SJ, Sivertz, M, Thomas, D, Dorfan, D, Heusch, C, Hubbard, B, Litke, AL, Lockman, WS, Pitzl, D, Sadrozinski, H, Seiden, A, Kawai, H, Campagneri, C, Eno, S, Frisch, H, Gross-Pilcher, C, Miller, M, Rosenberg, L, Shochet, M, Sullivan, G, Baranko, GJ, Carr, J, Cheung, HWK, Cumalat, JP, Ford, WT, Nauenberg, U, Rankin, P, Smith, JG, Astakhov, VI, Batyunya, BV, Bischoff, A, Budagov, YA, Denisenko, KG, Denisenko, NL, Gerasimov, SB, Golovatyuk, VM, Guzik, Z, Khubua, DI, Kadyrov, R, Kharzjeev, YN, Kolpakov, IF, Kovalenko, AD, Levchanovsky, FV, Lomakin, YF, Malakhov, AI, Omelyanenko, AA, Panebratsev, YA, Puzynin, IV, Semenov, AA, Senner, AE, Sidorov, VT, Sinaev, AN, Sisakian, AN, Smirnov, V, Spassof, T, Tsyganov, EN, Tyapkin, IA, Velev, GV, Vinogradov, VB, Vodopyanov, AS, Brba, V, Zanevsky, Yu V, Zhuravlev, NI, Zimin, NI, Zinchenko, AI, Fortney, LR, Goshaw, AT, Kowald, W, Oh, SH, Robertson, WJ, Walker, WD, Amatuni, AC, Vartapetian, GA, Amidei, D, Atac, M, Baumbaugh, AE, Beretvas, A, Bernstein, R, Binkley, M, Bross, AD, Clark, AG, Cooper, JW, Eartly, DP, Elias, JE, Fast, R W, Finley, D, Foster, G W, Freeman, J, Gaines, I, Gourlay, SA, Green, DR, Hahn, SR, Harris, RM, Hauser, J, Huth, J, Kephart, RD, Kuzminski, J, Martin, PS, Mishina, M, Mukerjee, A, Nash, T, Newman-Holmes, C, Para, A, Patrick, J, Plunkett, R, Schmidt, EE, Segler, SL, Tkaczyk, S, Vidal, R, Wagner, RL, Yeh, GP, Yoh, J, Field, R, Harmon, J, Walker, J, Corden, M, Hagopian, V, Johnson, K, Wahl, H, Kawaguchi, M, Yoshida, H, Dvornik, AM, Maksimenko, NB, Brandenburg, G, Feldman, G, Franklin, M, Geer, S, Konigsberg, J, Oliver, J, Phillips, T, Wilson, R, Kenney, C, Parker, S, Chiba, Y, Ohsugi, T, Asai, M, Shioden, M, Goldberg, H, Margulies, S, Solomon, J, Downing, R, Errede, S, Gautier, A, Haney, M, Holloway, L, Karliner, I, Liss, A, O'Halloran, T, Thaler, J, Sheldon, P, Simaitis, V, Wiss, J, Blockus, D, Brabson, B, Dzierba, A, Hanson, G, Lou, X, Ogren, H, Rust, D, Hauptman, J, Bagger, JA, Barnett, BA, Blumenfeld, BJ, Fisher, PH, Matthews, JAJ, Abe, F, Amako, K, Arai, Y, Doi, Y, Fujii, H, Fukui, Y, Haruyama, T, Ikeda, H, Ikeda, M, Inaba, S, Inagaki, T, Iwasaki, H, Kabe, S, Kanzaki, J, Kim, SK, Kondo, T, Maki, A, Manabe, A, Noumachi, M, Odaka, S, Ogawa, K, Sakai, Y, Sakamoto, H, Shinkawa, T, Takaiwa, Y, Terada, S, Tsuboyama, T, Tsukada, K, Ujiie, N, Unno, Y, Watase, Y, Yamamoto, A, Yasu, Y, Krivan, F, Seman, M, Spalek, J, Kikuchi, R, Miyake, K, Abrams, GS, Barbaro-Galtieri, A, Barnett, RM, Cahn, RN, Eberhard, PH, Einsweiler, K, Ely, R, Gilchriese, MGD, Groom, DE, Haber, C, Hearty, C, Hinchliffe, I, Kadel, RW, Kadyk, JA, Levi, ME, Limon, PJ, Loken, SC, Nygren, DR, Palounek, APT, Pripstein, M, Shapiro, M, Siegrist, JL, Spieler, HG, Strovink, M, Wang, EM, Wenzel, WA, Bailey, J, Beck, GA, Dainton, JB, Gabathuler, E, Maxfield, SJ, Baden, AR, Ball, AH, Chang, CY, Fong, DG, Goodman, JA, Hadley, NJ, Jawahery, A, Kellogg, RG, Kunori, S, Skuja, A, Zorn, GT, Ball, RC, Campbell, M, Chapman, J, Gustafson, HR, Hong, S, Jones, LW, Longo, MJ, Marcin, MR, Neal, HA, Nitz, D, Roe, BP, Snow, G, Thun, R, Border, P, Courant, H, Heller, K, Kubota, Y, Marshak, M, Peterson, E, Poling, R, Ruddick, K, Kulchitsky, JA, Moroz, LG, Moore, D, Summers, D, Nakamura, T, Nakamura, M, Niwa, K, Miyano, K, Miyata, H, Bishop, J, Biswas, N, Cason, N, Godfrey, J, Kenney, VP, Piekarz, J, Ruchti, R, Shephard, W, Alley, G, Alsmiller, RG, Alsmiller, FS, Fu, CY, Glover, CW, Vandergriff, D, Byslma, B, Durkin, LS, Ling, TY, Park, SK, Romanowski, TA, Tamura, N, Okusawa, T, Takahashi, T, Teramoto, Y, Yoshida, T, Nagashima, Y, Sugimoto, S, Cashmore, R, Harnew, N, Nickerson, R, Weidberg, A, Williams, W, Gladney, L, Hollebeek, RJ, Newcomer, M, Ragan, KJ, Sinervo, PK, Williams, HH, Armstrong, TA, Hartman, KW, Hasan, A, Heppelmann, SF, Lewis, RA, Minor, ED, Oh, BY, Smith, GA, Toothacker, WS, Whitmore, J, Amendolia, R, Bedeschi, F, Bellettini, G, Galeotti, S, Grassman, H, Mangano, ML, Menzione, A, Pauletta, G, Passuello, D, Punzi, G, Ristori, L, Engels, EE, Humanic, T, Mani, S, Shepard, PF, Barnes, VE, Garfinkel, AF, Koltick, DS, Laasanen, AT, McIlwain, R, Miller, DH, Shibata, E, Shipsey, IP, Adams, D, Ahmad, S, Bonner, B, Corcoran, M, Miettinen, H, Mutchler, G, Roberts, J, Skeens, J, Bodek, A, Lobkowicz, F, Sill, A, Slattery, P, Thorndike, EH, Giodaris, N, Goulianos, K, Melese, P, Rusack, R, White, S, Devlin, T, Watts, T, Gee, N, Harvey, JA, Murakami, A, Kobayashi, S, Masuda, K, Tsenov, RV, Iordanov, AB, Lankford, A, Bintinger, D, Johnstad, H, Aliev, Sh, Alimov, M, Gulamov, K, Kan, S, Kaprior, V, Khaneles, A, Myalkovsky, V, Pak, A, Surlin, E, Turdaliev, K, Yuldashev, A, Yuldashev, B, Amaglobeli, NS, Chiladze, BG, Hubua, DI, Salukvadze, RG, McIntyre, PM, Bowcock, TJV, Huson, FR, White, J T, Chaney, RC, Fenyves, EJ, Hammack, H, Orgeron, J, Lowery, WB, Johnson, NP, Higuchi, M, Hoshi, Y, Abe, K, Hasegawa, K, Yuta, H, Kato, S, Nishikawa, K, Homma, S, Miyachi, T, Watanabe, Y, Tanimori, T, Chiba, M, Hamatsu, R, Hirose, T, Kitamura, S, Emura, T, Takahashi, K, Funayama, Y, Hara, K, Kanda, S, Kaneko, T, Kim, S, Kondo, K, Mimashi, T, Miyashita, S, Morita, Y, Nakano, I, Sakurabata, H, Takikawa, K, Yasuoka, K, Asano, Y, Mori, S, Takada, Y, Kafka, T, Mann, WA, Milburn, RH, Napier, A, Sliwa, K, Lu, B, Mo, LW, Piilonen, LE, Daigo, M, Davisson, RJ, Liang, G, Lubatti, HJ, Wilkes, RJ, Zhao, T, Bellinger, J, Carlsmith, D, Erwin, A, Foudas, C, Handler, R, Loveless, R, Ott, G, Reeder, DD, Smith, W, Wendt, C, and Wu, SL

28. Noninvasive approach to assess coronary artery stenoses and ischemia.

Author: Johnson NP, Kirkeeide RL, Gould KL, Johnson, Nils P, Kirkeeide, Richard L, and Gould, K Lance
Published: 2013
Full Text: View/download PDF

29. Letter to the Editor regarding "PET: is myocardial flow quantification a clinical reality?".

Author: Johnson NP, Gould KL, Johnson, Nils P, and Gould, K Lance
Published: 2012
Full Text: View/download PDF

30. Revascularization Decisions in Patients With Stable Angina and Intermediate Lesions

Author: Stylianos A. Pyxaras, Nils P. Johnson, Bernard De Bruyne, Frederic De Vroey, Emanuele Barbato, Giuseppe Di Gioia, Luigi Di Serafino, Gabor G. Toth, Mariano Pellicano, Dan Rusinaru, Carlos Van Mieghem, Guy R. Heyndrickx, William Wijns, Balint Toth, Toth, Gg, Toth, B, Johnson, Np, De Vroey, F, Di Serafino, L, Pyxaras, S, Rusinaru, D, Di Gioia, G, Pellicano, M, Barbato, Emanuele, Van Mieghem, C, Heyndrickx, Gr, De Bruyne, B, and Wijns, W.
Subjects: medicine.medical_specialty, medicine.diagnostic_test, Interventional cardiology, business.industry, medicine.medical_treatment, Ischemia, International survey, medicine.disease, Revascularization, Coronary artery disease, Stenosis, Internal medicine, Intravascular ultrasound, medicine, Cardiology, Radiology, Cardiology and Cardiovascular Medicine, business, Cardiac catheterization
Abstract: Background— Fractional flow reserve (FFR) measurement of intermediate coronary stenoses is recommended by guidelines when demonstration of ischemia by noninvasive testing is unavailable. The study aims to evaluate the penetration of this recommendation into current thinking about revascularization strategies for stable coronary artery disease. Methods and Results— International Survey on Interventional Strategy was conducted via a web-based platform. First, participants’ experiences in interventional cardiology were queried. Second, 5 complete angiograms were provided, presenting only focal intermediate stenoses. FFR and quantitative coronary angiography values were known; however, remained undisclosed. Determination of stenosis significance was asked for each lesion. In cases of uncertainty, the most appropriate adjunctive invasive diagnostic method among quantitative coronary angiography, intravascular ultrasound, optical coherence tomography, or FFR needed to be selected. International Survey on Interventional Strategy was taken by 495 participants who provided 4421 lesion evaluations. In 3158 (71%) decisions, participants relied solely on angiographic appearance that was discordant in 47% with the known FFR, using 0.80 as cutoff value. The use of FFR and imaging modalities was requested in 21% and 8%, respectively. Comparing 4 groups of participants according to the experience in FFR, angiogram-based decisions were less frequent with increasing experience (77% versus 72% versus 69% versus 67%, respectively; P P P Conclusions— The findings confirm that, even when all potential external constraints are virtually eliminated, visual estimation continues to dominate the treatment decisions for intermediate stenoses, indicative of a worrisome disconnect between recommendations and current practice.
Published: 2014

31. A prospective natural history study of coronary atherosclerosis using fractional flow reserve

Author: Gabor G. Toth, Emanuele Barbato, Nick Curzen, Bernard De Bruyne, Nico H.J. Pijls, William F. Fearon, Gilles Rioufol, Zsolt Piroth, Pim A.L. Tonino, Peter Jüni, Nils P. Johnson, Cardiovascular Biomechanics, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Barbato, Emanuele, Toth, Gg, Johnson, Np, Pijls, Nhj, Fearon, Wf, Tonino, Pal, Curzen, N, Piroth, Z, Rioufol, G, Juni, P, and De Bruyne, B.
Subjects: Male, medicine.medical_specialty, stable angina, Percutaneous, Time Factors, [SDV]Life Sciences [q-bio], clinical outcome, Fractional flow reserve, Coronary Artery Disease, 030204 cardiovascular system & hematology, Coronary Angiography, Severity of Illness Index, vessel related, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Percutaneous Coronary Intervention, Internal medicine, medicine, Humans, 030212 general & internal medicine, Prospective Studies, cardiovascular diseases, fractional flow reserve, Coronary atherosclerosis, business.industry, Middle Aged, medicine.disease, Atherosclerosis, Prognosis, Coronary Vessels, 3. Good health, Surgery, Fractional Flow Reserve, Myocardial, Stenosis, Conventional PCI, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Mace, Natural history study, Follow-Up Studies
Abstract: International audience; BACKGROUND: In patients with coronary artery disease, clinical outcome depends on the extent of reversible myocardial ischemia. Whether the outcome also depends on the severity of the stenosis as determined by fractional flow reserve (FFR) remains unknown. OBJECTIVES: This study sought to investigate the relationship between FFR values and vessel-related clinical outcome. METHODS: We prospectively studied major adverse cardiovascular events (MACE) at 2 years in 607 patients in whom all stenoses were assessed by FFR and who were treated with medical therapy alone. The relationship between FFR and 2-year MACE was assessed as a continuous function. Logistic and Cox proportional hazards regression models were used to calculate the average decrease in the risk of MACE per 0.05-U increase in FFR. RESULTS: MACE occurred in 272 (26.5%) of 1,029 lesions. Target lesions with diameter stenosis \textgreater/=70% were more often present in the MACE group (p \textless 0.01). Median FFR was significantly lower in the MACE group versus the non-MACE group (0.68 [interquartile range: 0.54 to 0.77] vs. 0.80 [interquartile range: 0.70 to 0.88]; p \textless 0.01). The cumulative incidence of MACE significantly increased with increasing FFR quartiles. An average decrease in MACE per 0.05-unit increase in FFR was statistically significant even after adjustment for all clinical and angiographic features (odds ratio: 0.81; 95% confidence interval: 0.76 to 0.86]). The strongest increase in MACE occurred for FFR values between 0.80 and 0.60. In multivariable Cox regression analysis, FFR was significantly associated with MACE up to 2 years (hazard ratio: 0.87; 95% confidence interval: 0.83 to 0.91]). CONCLUSIONS: In patients with stable coronary disease, stenosis severity as assessed by FFR is a major and independent predictor of lesion-related outcome. (FAME II - Fractional Flow Reserve [FFR] Guided Percutaneous Coronary Intervention [PCI] Plus Optimal Medical Treatment [OMT] Verses OMT; NCT01132495).
Published: 2016

32. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes

Author: Johnson, N.P., Toth, G.G., Lai, D., Zhu, H., Acar, G., Agostoni, P., Appelman, Y., Arslan, F., Barbato, E., Chen, S.-L., Di Serafino, L., Dominguez-Franco, A.J., Dupouy, P., Esen, A.M., Esen, O.B., Hamilos, M., Iwasaki, K., Jensen, L.O., Jimenez-Navarro, M.F., Katritsis, D.G., Kocaman, S.A., Koo, B.-K., Lopez-Palop, R., Lorin, J.D., Miller, L.H., Muller, O., Nam, C.-W., Oud, N., Puymirat, E., Rieber, J., Rioufol, G., Rodes-Cabau, J., Sedlis, S.P., Takeishi, Y., Tonino, P.A.L., Van Belle, E., Verna, E., Werner, G.S., Fearon, W.F., Pijls, N. H. J., De Bruyne, B., Gould, K.L., Cardiology, ICaR - Heartfailure and pulmonary arterial hypertension, Johnson, Np, T?th, Gg, Lai, D, Zhu, H, A?ar, G, Agostoni, P, Appelman, Y, Arslan, F, Barbato, Emanuele, Chen, Sl, Di Serafino, L, Dom?nguez Franco, Aj, Dupouy, P, Esen, Am, Esen, Ob, Hamilos, M, Iwasaki, K, Jensen, Lo, Jim?nez Navarro, Mf, Katritsis, Dg, Kocaman, Sa, Koo, Bk, L?pez Palop, R, Lorin, Jd, Miller, Lh, Muller, O, Nam, Cw, Oud, N, Puymirat, E, Rieber, J, Rioufol, G, Rod?s Cabau, J, Sedlis, Sp, Takeishi, Y, Tonino, Pa, Van Belle, E, Verna, E, Werner, G, Fearon, Wf, Pijls, Nh, De Bruyne, B, Gould, Kl, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), and Cardiovascular Biomechanics
Subjects: [SDV]Life Sciences [q-bio], Coronary Artery Disease, Kaplan-Meier Estimate, Prognosis, Fractional Flow Reserve, Severity of Illness Index, meta-analysis, Coronary Artery Disease/*diagnosis/mortality/*physiopathology, Fractional Flow Reserve, Myocardial, Treatment Outcome, Myocardial/*physiology, threshold, Humans, prognosis, fractional flow reserve
Abstract: BACKGROUND: Fractional flow reserve (FFR) has become an established tool for guiding treatment, but its graded relationship to clinical outcomes as modulated by medical therapy versus revascularization remains unclear.OBJECTIVES: The study hypothesized that FFR displays a continuous relationship between its numeric value and prognosis, such that lower FFR values confer a higher risk and therefore receive larger absolute benefits from revascularization.METHODS: Meta-analysis of study- and patient-level data investigated prognosis after FFR measurement. An interaction term between FFR and revascularization status allowed for an outcomes-based threshold.RESULTS: A total of 9,173 (study-level) and 6,961 (patient-level) lesions were included with a median follow-up of 16 and 14 months, respectively. Clinical events increased as FFR decreased, and revascularization showed larger net benefit for lower baseline FFR values. Outcomes-derived FFR thresholds generally occurred around the range 0.75 to 0.80, although limited due to confounding by indication. FFR measured immediately after stenting also showed an inverse relationship with prognosis (hazard ratio: 0.86, 95% confidence interval: 0.80 to 0.93; p < 0.001). An FFR-assisted strategy led to revascularization roughly half as often as an anatomy-based strategy, but with 20% fewer adverse events and 10% better angina relief.CONCLUSIONS: FFR demonstrates a continuous and independent relationship with subsequent outcomes, modulated by medical therapy versus revascularization. Lesions with lower FFR values receive larger absolute benefits from revascularization. Measurement of FFR immediately after stenting also shows an inverse gradient of risk, likely from residual diffuse disease. An FFR-guided revascularization strategy significantly reduces events and increases freedom from angina with fewer procedures than an anatomy-based strategy.
Published: 2014

33. The optical Fano resonance in asymmetric dimer metamaterial

Author: Antonello Andreone, Giancarlo Abbate, Volodymyr Tkachenko, Ndubuisi E. J. Omaghali, Boardman, AD, Johnson, NP, Ziolkowski, RW, Omaghali, Nej, Tkachenko, V, Andreone, Antonello, and Abbate, Giancarlo
Subjects: Physics, business.industry, Physics::Optics, Resonance, Fano resonance, Metamaterial, Dielectric, Molecular physics, Symmetry (physics), Optics, Dispersion (optics), Nanorod, business, Excitation
Abstract: We study the sharp Fano-type resonance in a dimer metamaterial based on nanorods with different lengths. Breaking the length symmetry results in the excitation of a dark mode that weakly couples to the free space. Interference between the dark mode and the higher frequency bright mode gives rise to the peculiar asymmetric and sharp profile of the resonance. The steep dispersion and high sensitivity to slight variations of the dielectric environment of this resonance envisage the possible application of the asymmetric dimer metamaterial as an optical sensor for chemical or biological analysis.
Published: 2012

34. Transitions From Basic Experimental to Clinical Coronary Pathophysiology for Guiding Chronic CAD Management.

Author: Gould KL and Johnson NP
Published: 2024
Full Text: View/download PDF

35. Domestic groundwater wells in Appalachia show evidence of low-dose, complex mixtures of legacy pollutants.

Author: Bugher NA, Xiong B, Gentles RI, Glist LD, Siegel HG, Johnson NP, Clark CJ, Deziel NC, Saiers JE, and Plata DL
Abstract: Lack of water quality data for private drinking water sources prevents robust evaluation of exposure risk for communities co-located with historically contaminated sites and ongoing industrial activity. Areas of the Appalachian region of the United States ( i.e. , Pennsylvania, Ohio and West Virginia) contain extensive hydraulic fracturing activity, as well as other extractive and industrial technologies, in close proximity to communities reliant on private drinking water sources, creating concern over potential groundwater contamination. In this study, we characterized volatile organic compound (VOC) occurrence at 307 private groundwater well sites within Pennsylvania, Ohio, and West Virginia. The majority (97%) of water samples contained at least one VOC, while the average number of VOCs detected at a given site was 5 ± 3. The majority of individual VOC concentrations fell below applicable U.S. Environmental Protection Agency (EPA) Maximum Contamination Levels (MCLs), except for chloroform (MCL of 80 μg L -1 ; n = 1 at 98 μg L -1 ), 1,2-dibromoethane (MCL of 0.05 μg L -1 ; n = 3 ranging from 0.05 to 0.35 μg L -1 ), and 1,2-dibromo-3-chloropropane (MCL of 0.2 μg L -1 ; n = 7 ranging from 0.20 to 0.58 μg L -1 ). To evaluate well susceptibility to VOCs from industrial activity, distance to hydraulic fracturing site was used to assess correlations with contaminant occurrences. Proximity to closest hydraulic fracturing well-site revealed no statistically significant linear relationships with either individual VOC concentrations, or frequency of VOC detections. Evaluation of other known industrial contamination sites ( e.g. , US EPA Superfund sites) revealed elevated levels of three VOCs (chloroform, toluene, benzene) in groundwaters within 10 km of those Superfund sites in West Virginia and Ohio, illuminating possible point source influence. Lack of correlation between VOC concentrations and proximity to specific point sources indicates complex geochemical processes governing trace VOC contamination of private drinking water sources. While individual concentrations of VOCs fell well below recommended human health levels, the low dose exposure to multiple VOCs occurring in drinking supplies for Appalachian communities was noted, highlighting the importance of groundwater well monitoring.
Published: 2024
Full Text: View/download PDF

36. The role of advanced physiological guidance in contemporary coronary artery disease management.

Author: Munhoz D, Ikeda K, Bouisset F, Sakai K, Tajima A, Mizukami T, Sonck J, Johnson NP, and Collet C
Subjects: Humans, Clinical Decision-Making, Disease Management, Coronary Artery Disease therapy, Coronary Artery Disease physiopathology, Percutaneous Coronary Intervention methods, Fractional Flow Reserve, Myocardial physiology
Abstract: Purpose of Review: This review evaluates the emerging role of the pullback pressure gradient (PPG) as a standardized metric for assessing coronary artery disease (CAD) patterns and its implications for clinical decision-making when managing patients undergoing percutaneous coronary interventions (PCIs). By integrating PPG with existing physiological assessments, this review highlights the potential benefits of PPG in predicting treatment outcomes and refining therapeutic strategies for CAD., Recent Findings: Recent studies, particularly the PPG Global study have demonstrated a strong correlation between PPG values and post-PCI outcomes, revealing that focal disease is associated with improved fractional flow reserve (FFR) and lower rates of adverse events than vessels with diffuse disease (low PPG). Additionally, PPG has been linked to specific atherosclerotic plaque characteristics, indicating its utility in identifying high-risk plaques. The integration of PPG with advanced imaging techniques further enhances the understanding of CAD patterns and their implications for treatment planning., Summary: The PPG represents a significant advancement in the management of CAD, providing a reproducible and objective assessment of coronary artery disease patterns that can inform clinical decision-making. As research continues to explore the relationship among PPG, atherosclerotic characteristics, and patient outcomes, its integration into routine practice is expected to improve the effectiveness of PCI and optimize patient management strategies. Future studies are warranted to establish specific PPG thresholds and further investigate its potential in identifying vulnerable plaques and guiding treatment decisions., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Published: 2024
Full Text: View/download PDF

37. Systematic review and meta-analysis of randomized and nonrandomized studies on fractional flow reserve-guided revascularization.

Author: Mangiacapra F, Paolucci L, Johnson NP, Viscusi MM, Ussia GP, Grigioni F, De Bruyne B, and Barbato E
Subjects: Humans, Coronary Angiography, Non-Randomized Controlled Trials as Topic, Percutaneous Coronary Intervention methods, Randomized Controlled Trials as Topic, Coronary Artery Disease surgery, Coronary Artery Disease physiopathology, Coronary Artery Disease diagnosis, Fractional Flow Reserve, Myocardial physiology, Myocardial Revascularization methods
Abstract: Introduction and Objectives: Several studies have investigated the effectiveness of fractional flow reserve (FFR) guidance in improving clinical outcomes after myocardial revascularization, yielding conflicting results. The aim of this study was to compare clinical outcomes in patients with coronary artery disease following FFR-guided or angiography-guided revascularization., Methods: Both randomized controlled trials (RCTs) and nonrandomized intervention studies were included. Coprimary endpoints were all-cause death, myocardial infarction, and major adverse cardiovascular events (MACE). The study is registered with PROSPERO (CRD42022344765)., Results: A total of 30 studies enrolling 393 588 patients were included. FFR-guided revascularization was associated with significantly lower rates of all-cause death (OR, 0.63; 95%CI, 0.53-0.73), myocardial infarction (OR, 0.70; 95%CI, 0.59-0.84), and MACE (OR, 0.77; 95%CI, 0.70-0.85). When only RCTs were considered, no significant difference between the 2 strategies was observed for any endpoints. However, the use of FFR was associated with reduced rates of revascularizations and treated lesions. Metaregression suggested that the higher the rate of revascularized patients the lower the benefit of FFR guidance on MACE reduction compared with angiography guidance (P=.012). Similarly, higher rates of patients with acute coronary syndromes were associated with a lower benefit of FFR-guided revascularization (P=.039)., Conclusions: FFR-guided revascularization was associated with lower rates of all-cause death, myocardial infarction and MACE compared with angiographic guidance, with RCTs and nonrandomized intervention studies yielding conflicting data. The benefits of FFR-guidance seem to be less evident in studies with high revascularization rates and with a high prevalence of patients with acute coronary syndrome., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
Published: 2024
Full Text: View/download PDF

38. Hybrid quantification of absolute perfusion requires accurate measurement of myocardial mass.

Author: Johnson NP and Gould KL
Subjects: Humans, Myocardium pathology, Coronary Circulation, Coronary Angiography methods, Myocardial Perfusion Imaging methods
Published: 2024
Full Text: View/download PDF

39. Unraveling aortic hemodynamics using fluid structure interaction: biomechanical insights into bicuspid aortic valve dynamics with multiple aortic lesions.

Author: Govindarajan V, Wanna C, Johnson NP, Kolanjiyil AV, Kim H, Kitkungvan D, McPherson DM, Grande-Allen J, Chandran KB, Estrera A, Ramzy D, and Prakash S
Abstract: Aortic lesions, exemplified by bicuspid aortic valves (BAVs), can complicate congenital heart defects, particularly in Turner syndrome patients. The combination of BAV, dilated ascending aorta, and an elongated aortic arch presents complex hemodynamics, requiring detailed analysis for tailored treatment strategies. While current clinical decision-making relies on imaging modalities offering limited biomechanical insights, integrating high-performance computing and fluid-structure interaction algorithms with patient data enables comprehensive evaluation of diseased anatomy and planned intervention. In this study, a patient-specific workflow was utilized to biomechanically assess a Turner syndrome patient's BAV, dilated ascending aorta, and elongated arch. Results showed significant improvements in valve function (effective orifice area, EOA increased approximately twofold) and reduction in valve stress (~ 1.8-fold) following virtual commissurotomy, leading to enhanced flow dynamics and decreased viscous dissipation (~ twofold) particularly in the ascending aorta. However, increased viscous dissipation in the distal transverse aortic arch offset its local reduction in the AAo post-intervention, emphasizing the elongated arch's role in aortic hemodynamics. Our findings highlight the importance of comprehensive biomechanical evaluation and integrating patient-specific modeling with conventional imaging techniques for improved disease assessment, risk stratification, and treatment planning, ultimately enhancing patient outcomes., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Published: 2024
Full Text: View/download PDF

40. How to differentiate obstructive from non-obstructive CAD with quantitative PET MPI using coronary flow capacity.

Author: Johnson NP and Gould KL
Published: 2024
Full Text: View/download PDF

41. Influence of Pathophysiologic Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes.

Author: Collet C, Munhoz D, Mizukami T, Sonck J, Matsuo H, Shinke T, Ando H, Ko B, Biscaglia S, Rivero F, Engstrøm T, Arslani K, Leone AM, van Nunen LX, Fearon WF, Christiansen EH, Fournier S, Desta L, Yong A, Adjedj J, Escaned J, Nakayama M, Eftekhari A, Zimmermann FM, Sakai K, Storozhenko T, da Costa BR, Campo G, West NEJ, De Potter T, Heggermont W, Buytaert D, Bartunek J, Berry C, Collison D, Johnson T, Amano T, Perera D, Jeremias A, Ali Z, Pijls NHJ, De Bruyne B, and Johnson NP
Subjects: Humans, Female, Male, Aged, Middle Aged, Prospective Studies, Treatment Outcome, Percutaneous Coronary Intervention adverse effects, Coronary Artery Disease physiopathology, Coronary Artery Disease therapy, Fractional Flow Reserve, Myocardial
Abstract: Background: Diffuse coronary artery disease affects the safety and efficacy of percutaneous coronary intervention (PCI). Pathophysiologic coronary artery disease patterns can be quantified using fractional flow reserve (FFR) pullbacks incorporating the pullback pressure gradient (PPG) calculation. This study aimed to establish the capacity of PPG to predict optimal revascularization and procedural outcomes., Methods: This prospective, investigator-initiated, single-arm, multicenter study enrolled patients with at least one epicardial lesion with an FFR ≤0.80 scheduled for PCI. Manual FFR pullbacks were used to calculate PPG. The primary outcome of optimal revascularization was defined as an FFR ≥0.88 after PCI., Results: A total of 993 patients with 1044 vessels were included. The mean FFR was 0.68±0.12, PPG 0.62±0.17, and the post-PCI FFR was 0.87±0.07. PPG was significantly correlated with the change in FFR after PCI (r=0.65 [95% CI, 0.61-0.69]; P <0.001) and demonstrated excellent predictive capacity for optimal revascularization (area under the receiver operating characteristic curve, 0.82 [95% CI, 0.79-0.84]; P <0.001). FFR alone did not predict revascularization outcomes (area under the receiver operating characteristic curve, 0.54 [95% CI, 0.50-0.57]). PPG influenced treatment decisions in 14% of patients, redirecting them from PCI to alternative treatment modalities. Periprocedural myocardial infarction occurred more frequently in patients with low PPG (<0.62) compared with those with focal disease (odds ratio, 1.71 [95% CI, 1.00-2.97])., Conclusions: Pathophysiologic coronary artery disease patterns distinctly affect the safety and effectiveness of PCI. PPG showed an excellent predictive capacity for optimal revascularization and demonstrated added value compared with an FFR measurement., Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04789317., Competing Interests: Dr Collet reports receiving research grants from Biosensors, Coroventis Research, Medis Medical Imaging, Pie Medical Imaging, CathWorks, Boston Scientific, Siemens, HeartFlow, and Abbott Vascular; consultancy fees from HeartFlow, OpSens Medical, Abbott Vascular, and Philips Volcano; and has patents pending on diagnostic methods for coronary artery disease. Dr Munhoz reports a research grant provided by the CardioPath PhD programme and speaker fees from Abbott Vascular. Dr Mizukami reports receiving research grants from Boston Scientific and speaker fees from Abbott Vascular, CathWorks, and Boston Scientific. Dr Matsuo has received consulting fees from Kaneka and Zeon and speaker’s fees from Abbott Medical Japan, Boston Scientific, Philips, and Amgen. Dr Ko has received consulting fees from Canon Medical, Abbott, and Medtronic. Dr Biscaglia received research grants provided by Sahajanand Medical Technologies, Medis Medical Imaging, Eukon Srl, Siemens Healthineers, General Electric Healthcare, and Insight Lifetech. Dr Engstrøm reports speaker and advisory board fees from Abbott, Boston Scientific, and Novo Nordisk. Dr Leone reports receiving consultancy fees from Abbott and honoraria for sponsored symposia from Abbott, Medtronic, and Abiomed. Dr Fearon receives institutional research support from Abbott, Boston Scientific, and Medtronic and has consulting relationships with CathWorks and Siemens and stock options from HeartFlow. Dr Christiansen has received consulting fees from Abbott Medical Denmark A/S. Dr Yong has received minor honoraria from Abbott Vascular and research grants from Abbott Vascular and Philips. Dr Escaned is supported by the Intensification of Research Activity project INT22/00088 from the Spanish Instituto de Salud Carlos III and received speaker and advisory board member fees from Abbott and Philips. Dr Storozhenko reports a grant provided by the EAPCI Fellowship Programme. Dr West is an employee of Abbott Vascular. Dr De Potter is a paid consultant for Biosense Webster and receives grant support (institutional) and consultancy fees (institutional) from Abbott. Dr Berry receives research funding from the British Heart Foundation (grants RE/18/6134217, BHF/FS/17/26/32744, and PG/19/28/34310) and is employed by the University of Glasgow, which holds consultancy and research agreements for his work with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Coroventis Research, GlaxoSmithKline, HeartFlow, Menarini, Novartis, Servier, Siemens Healthcare, and Valo Health. Dr Collison has received consulting fees from Abbott. Dr Johnson has received consultancy or speaker fees from Abbott Vascular, Boston Scientific, Medtronic, Shockwave, and Terumo, and research grants from Abbott Vascular. Dr Amano reports receiving lecture fees from Astellas Pharma, Astra Zeneca, Bayer, Daiichi Sankyo, and Bristol Myers Squibb. Dr Perera has received research grant support from Abbott Vascular, HeartFlow, and Philips. Dr Jeremias has received consulting fees from Canon Medical, Artrya Medical, and Boston Scientific. Dr Ali reports institutional grant support from Abbott, Abiomed, Acist, Amgen, Boston Scientific, CathWorks, Canon Medical, Conavi, HeartFlow, Inari, Medtronic, the US National Institutes of Health, Nipro, OpSens Medical, Medis, Philips, Shockwave, Siemens, SpectraWAVE, and Teleflex; consulting fees from Abiomed, Astra Zeneca, Boston Scientific, CathWorks, OpSens Medical, Philips, and Shockwave; and equity in Elucid, Lifelink, SpectraWAVE, Shockwave, and VitalConnect. Dr Pijls has received research grants from Abbott and Hexacath; consultancy fees from Abbott, GE, Philips, and HeartFlow; and has equity in General Electric, Philips, and HeartFlow. Dr De Bruyne reports receiving consultancy fees from Boston Scientific and Abbott and research grants from Coroventis Research, Pie Medical Imaging, CathWorks, Boston Scientific, Siemens, HeartFlow, and Abbott Vascular. Dr Johnson received internal funding from the Weatherhead PET Center for Preventing and Reversing Atherosclerosis; has received significant institutional research support from St Jude Medical (CONTRAST [Can Contrast Injection Better Approximate FFR Compared to Pure Resting Physiology?; URL: https://www.clinicaltrials.gov; Unique identifier: NCT02184117]) and Philips Volcano (DEFINE-FLOW [Combined Pressure and Flow Measurements to Guide Treatment of Coronary Stenoses; URL: https://www.clinicaltrials.gov; Unique identifier: NCT02328820]) for other studies using intracoronary pressure and flow sensors; has an institutional licensing agreement with Boston Scientific for the smart-minimum FFR algorithm (now commercialized under 510[k] K191008); and has patents pending on diagnostic methods for quantifying aortic stenosis and TAVI physiology and on methods to correct pressure tracings from fluid-filled catheters.
Published: 2024
Full Text: View/download PDF

42. Quantitative myocardial perfusion in liver transplantation candidates: Poorly metabolized caffeine inhibition of vasodilatory stress.

Author: Kitkungvan D, Johnson NP, Roby AE, Mendoza P, Bui L, Patel MB, Sander K, Harmon L, Kirkeeide R, and Gould KL
Subjects: Humans, Male, Female, Middle Aged, Coronary Circulation drug effects, Positron-Emission Tomography, Aged, Adult, Vasodilation drug effects, Caffeine blood, Liver Transplantation, Vasodilator Agents, Dipyridamole, Myocardial Perfusion Imaging methods, Dobutamine
Abstract: Background: Data on cardiac positron emission tomography (PET) in liver transplantation (LT) candidates are limited with no prior study accounting for poorly metabolized caffeine reducing stress perfusion., Method: Consecutive LT candidates (n = 114) undergoing cardiac rest/stress PET were instructed to abstain from caffeine for 2 days extended to 5 and 7 days. Due to persistently high prevalence of measurable blood caffeine after 5-day caffeine abstinence, dipyridamole (n = 41) initially used was changed to dobutamine (n = 73). Associations of absolute flow, coronary flow reserve (CFR), detectable blood caffeine, and Modified End-Stage Liver Disease (MELD) score for liver failure severity were evaluated. Coronary flow data of LT candidates were compared to non-LT control group (n = 102 for dipyridamole, n = 29 for dobutamine)., Results: Prevalence of patients with detectable blood caffeine was 63.3%, 36.7% and 33.3% after 2-, 5- and 7-day of caffeine abstinence, respectively. MELD score was associated with detectable caffeine (odd ratio 1.18,P < 0.001). CFR was higher during dipyridamole stress without-caffeine versus with-caffeine (2.22 ± 0.80 vs 1.55 ± 0.37,P = 0.048) but lower than dobutamine stress (2.22 ± 0.80 vs 2.82 ± 1.02,P = 0.026). Mediation analysis suggested that the dominant association between CFR and MELD score in dipyridamole group derived from caffeine-impaired CFR and liver failure/caffeine interaction. CFR in LT candidates was lower than non-LT control population in both dipyridamole and dobutamine group., Conclusion: We demonstrate exceptionally high prevalence of detectable blood caffeine in LT candidates undergoing stress PET myocardial perfusion imaging resulting in reduced CFR with dipyridamole compared to dobutamine. The delayed caffeine clearance in LT candidates makes dobutamine a preferred stress agent in this population., (Copyright © 2024 University of Texas Health Science Center at Houston. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

43. Microvascular resistance reserve: Impact of autoregulation on its conceptual framework and practical implementation.

Author: Johnson NP, Kirkeeide RL, and Gould KL
Subjects: Humans, Microvessels physiopathology, Microcirculation, Homeostasis, Vascular Resistance
Published: 2024
Full Text: View/download PDF

44. Iodine and other factors associated with fertility outcome following oil-soluble contrast medium hysterosalpingography: a prospective cohort study.

Author: Mathews DM, Peart JM, Sim RG, Johnson NP, O'Sullivan S, Derraik JGB, and Hofman PL
Subjects: Humans, Female, Adult, Prospective Studies, Pregnancy, Infertility, Female epidemiology, Hypothyroidism drug therapy, Hypothyroidism epidemiology, Fertility drug effects, New Zealand epidemiology, Oils, Cohort Studies, Thyroid Function Tests, Iodine urine, Iodine deficiency, Hysterosalpingography methods, Contrast Media, Pregnancy Rate
Abstract: Objective: To examine factors associated with fertility following hysterosalpingography (HSG) using an oil-soluble contrast medium (OSCM)., Design: In a prospective cohort study on 196 women undergoing OSCM HSG, we showed that iodine excess was almost universal (98%) and mild subclinical hypothyroidism was frequent (38%). Here, we report the analyses of secondary outcomes examining factors associated with the likelihood of pregnancy following the HSG., Setting: Auckland, New Zealand (2019-2021)., Sample: 196 women with primary or secondary infertility who underwent OSCM HSG., Methods: Baseline and serial urine iodine concentrations (UIC) and thyroid function tests were measured over six months following the HSG. Pregnancy and treatment with levothyroxine during the study period were documented., Results: Following OSCM HSG, pregnancy rates were 49% in women aged <40 years (77/158) but considerably lower (16%) among those ≥40 years (6/38). Similarly, live birth rates were markedly lower in women ≥40 years (17%; 1/6) versus <40 years (73%; 56/77). 29% of participants were iodine deficient at baseline despite advice recommending iodine fortification. Following HSG, the likelihood of pregnancy in women with moderate iodine deficiency was 64% higher than in women with normal iodine levels (p=0.048). Among women aged <40 years who had subclinical hypothyroidism (n=75), levothyroxine treatment was associated with higher pregnancy rates compared to untreated women [63% (26/48) vs 37% (10/27), respectively; p=0.047]., Conclusion: OSCM HSG was associated with higher pregnancy rates in women ≤40 than in those aged >40 years. Iodine deficiency was relatively common in this cohort, and increased iodine levels from OSCM exposure may contribute to the improved fertility observed with this procedure., Trial Registration: This study is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR: 12620000738921) https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000738921., Competing Interests: NJ is involved in research with the University of Auckland and the University of Adelaide, which are funded by Guerbet. NJ has undertaken paid consultancies for Guerbet. DM and PH are involved with a University of Auckland study on Lipiodol safety through an unrestricted independent grant to the Liggins institute from Guerbet. PH has received fees for speaking in two webinars sponsored by Guerbet. RS and JP have been paid for presenting and being an advisory board member by Guerbet. RS, JP, and NJ undertake Lipiodol HSGs as a part of their profession. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funder Guerbet had no role in the study design, conduction of the study, data analyses or interpretation, manuscript preparation, decision to publish it, or dissemination of study findings., (Copyright © 2024 Mathews, Peart, Sim, Johnson, O’Sullivan, Derraik and Hofman.)
Published: 2024
Full Text: View/download PDF

45. Epicardial inflow versus myocardial distribution: average regional transmural coronary flow is not enough.

Author: Johnson NP and Gould KL
Subjects: Humans, Pericardium diagnostic imaging, Coronary Vessels diagnostic imaging, Coronary Vessels physiopathology, Coronary Circulation physiology
Published: 2024
Full Text: View/download PDF

46. How Do the Flow Components of Coronary Flow Reserve Change After Aortic Valve Replacement?

Author: Eerdekens R, Anderson HVS, and Johnson NP
Subjects: Humans, Aortic Valve surgery, Coronary Circulation, Blood Flow Velocity, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement
Abstract: Competing Interests: Declaration of Competing Interest Dr. Johnson reports no direct relations but, outside of the present work, receives internal funding from the Weatherhead PET Center for Preventing and Reversing Atherosclerosis; has patents pending on diagnostic methods for quantifying AS and TAVI physiology and on methods to correct pressure tracings from fluid-filled catheters; and receives significant institutional research support from Neovasc/Shockwave (positron emission tomography core laboratory for COSIRA-II, NCT05102019). The remaining authors have no competing interest to declare.
Published: 2024
Full Text: View/download PDF

47. Acute changes in microvascular resistance after treating aortic stenosis.

Author: Johnson NP and Eerdekens R
Published: 2024
Full Text: View/download PDF

48. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.

Author: Becker CM, Johnson NP, As-Sanie S, Arjona Ferreira JC, Abrao MS, Wilk K, Imm SJ, Mathur V, Perry JS, Wagman RB, and Giudice LC
Subjects: Humans, Female, Adolescent, Young Adult, Adult, Middle Aged, Dysmenorrhea complications, Dysmenorrhea drug therapy, Quality of Life, Pelvic Pain drug therapy, Pelvic Pain etiology, Analgesics, Opioid, Endometriosis complications, Endometriosis drug therapy, Dyspareunia drug therapy, Dyspareunia etiology, Phenylurea Compounds, Pyrimidinones
Abstract: Study Question: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain?, Summary Answer: For up to 2 years, treatment with relugolix CT improved menstrual and non-menstrual pain, dyspareunia, and function in women with endometriosis; after an initial decline of <1%, the mean bone mineral density (BMD) remained stable with continued treatment., What Is Known Already: Endometriosis is a chronic condition characterized by symptoms of dysmenorrhea, non-menstrual pelvic pain (NMPP), and dyspareunia, which have a substantial impact on the lives of affected women, their partners, and families. SPIRIT 1 and 2 were phase 3, randomized, double-blind, placebo-controlled studies of once-daily relugolix CT (relugolix 40 mg, oestradiol 1 mg, norethisterone acetate 0.5 mg) in premenopausal women (age 18-50 years) with endometriosis and moderate-to-severe dysmenorrhea and NMPP. These trials demonstrated a significant improvement of dysmenorrhea, NMPP, and dyspareunia in women treated with relugolix CT, with minimal decline (<1%) in BMD versus placebo at 24 weeks., Study Design, Size, Duration: Patients participating in this open-label, single-arm, long-term extension (LTE) study of the 24-week SPIRIT pivotal studies (SPIRIT 1 and 2) received up to an additional 80 weeks of once-daily oral relugolix CT treatment between May 2018 and January 2023., Participants/materials, Setting, Methods: Premenopausal women with confirmed endometriosis and moderate to severe dysmenorrhea and NMPP who completed the 24-week pivotal studies (SPIRIT 1 and 2 trials; Giudice et al., 2022) and who met all entry criteria were eligible to enrol. Two-year results were analysed by treatment group based on original randomization in pivotal studies: relugolix CT, delayed relugolix CT (relugolix 40 mg monotherapy for 12 weeks, followed by relugolix CT), or placebo→relugolix CT (placebo for 24 weeks followed by relugolix CT). The primary endpoints of the LTE study were the proportion of dysmenorrhea and NMPP responders at Week 52 and Week 104/end-of-treatment (EOT). A responder was a participant who achieved a predefined, clinically meaningful reduction from baseline in Numerical Rating Scale (NRS) scores (0 = no pain, 10 = worst pain imaginable) for the specific pain type with no increase in analgesic use. The predefined clinically meaningful threshold for dysmenorrhea was 2.8 points and for NMPP was 2.1 points. Secondary efficacy endpoints included change from baseline in Endometriosis Health Profile-30 (EHP-30) pain domain scores, a measure of the effects of endometriosis-associated pain on daily activities (function), NRS scores for dysmenorrhea, NMPP, dyspareunia, and overall pelvic pain, and analgesic/opioid use. Safety endpoints included adverse events and changes in BMD., Main Results and the Role of Chance: Of 1261 randomized patients, 1044 completed the pivotal studies, 802 enrolled in the LTE, 681 completed 52 weeks of treatment, and 501 completed 104 weeks of treatment. Demographics and baseline characteristics of the extension population were consistent with those of the original randomized population. Among patients randomized to relugolix CT at pivotal study baseline who continued in the LTE (N = 277), sustained improvements in endometriosis-associated pain were demonstrated through 104 weeks. The proportion of responders at Week 104/EOT for dysmenorrhea and NMPP was 84.8% and 75.8%, respectively. Decreases in dyspareunia and improvement in function assessed by EHP-30 pain domain were also sustained over 2 years. At Week 104/EOT, 91% of patients were opioid-free and 75% of patients were analgesic-free. Relugolix CT over 104 weeks was well tolerated with a safety profile consistent with that observed over the first 24 weeks. After initial least squares mean BMD loss <1% at Week 24, BMD plateaued at Week 36 and was sustained for the duration of 104 weeks of treatment. Efficacy and safety results were generally consistent in women in the placebo→relugolix CT and delayed relugolix CT groups., Limitations, Reasons for Caution: The study was conducted as an open-label study without a control group over the 80 weeks of the extension period. Of the 802 patients who were enrolled in this LTE study, 681 patients (84.9%) and 501 patients (62.5%) of patients completed 52 and 104 weeks of treatment, respectively. In addition, there currently are no comparative data to other hormonal medications. Finally, a third (37.4%) of the study population terminated participation early., Wider Implications of the Findings: In conclusion, relugolix CT offers an additional option to help address an important unmet clinical need for effective, safe, and well-tolerated medical treatments for endometriosis that can be used longer-term, reducing the need for opioids and improving quality of life. The findings from this study may help support the care of women with endometriosis seeking longer-term effective medical management of their symptoms., Study Funding/competing Interest(s): This study was funded by Myovant Sciences GmbH (now Sumitomo Pharma Switzerland GmbH). C.M.B. reports fees from Myovant, grants from Bayer Healthcare, fees from ObsEva, and Chair of ESHRE Endometriosis Guideline Group (all funds went to the University of Oxford); N.P.J. reports personal fees from Myovant Sciences, during the conduct of the study, personal fees from Guerbet, personal fees from Organon, personal fees from Roche Diagnostics; S.A.-S. reports personal fees from Myovant Sciences, personal fees from Bayer, personal fees from Abbvie, personal fees from UpToDate; J.S.P., and R.B.W. are employees and shareholders of Myovant Sciences; J.C.A.F. and S.J.I. are shareholders of Myovant Sciences (but at time of publicaion are no longer employess of Myovant Sciences); M.S.A. and K.W. have no conflicts to declare; V.M. is a consultant to Myovant; L.C.G. reports personal fees from Myovant Sciences, Inc and Bayer. The authors did not receive compensation for manuscript writing, review, and revision., Trial Registration Number: NCT03654274., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.)
Published: 2024
Full Text: View/download PDF

49. How might coronary sinus reducer treatment change myocardial perfusion?

Author: Bober RM and Johnson NP
Subjects: Humans, Angina Pectoris, Treatment Outcome, Perfusion, Coronary Sinus diagnostic imaging, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Myocardial Perfusion Imaging
Published: 2024
Full Text: View/download PDF

50. Should We Stent Vulnerable, But Asymptomatic, Lesions?

Author: Johnson NP, Gould KL, and Narula J
Subjects: Humans, Treatment Outcome, Stents, Ultrasonography, Interventional, Coronary Angiography, Coronary Vessels diagnostic imaging, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Fractional Flow Reserve, Myocardial
Abstract: Competing Interests: Funding Support and Author Disclosures Drs Johnson and Gould report no direct relationships but outside of the present work receive internal funding from the Weatherhead P.E.T. Imaging Center; and have patents pending on diagnostic methods for quantifying aortic stenosis and TAVI physiology, and on methods to correct pressure tracings from fluid-filled catheters. Dr Johnson has received institutional research support from Neovasc/Shockwave (PET core lab for COSIRA-II. Dr Gould is the 510(k) applicant for several cardiac PET software packages approved by the FDA (K113754, K143664, K171303, K202679, K231731) but does not receive any licensing fees paid to UTHealth by Bracco Diagnostics and GE Healthcare. Dr Narula has reported that he has no relationships relevant to the contents of this paper to disclose.
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

452 results on '"Johnson NP"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources